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 ABSTRACT 
 
A COMPARATIVE STUDY OF PULMONARY FUNCTION TEST 
ABNORMALITIES IN RHEUMATOID ARTHRITIS- TREATMENT 
NAIVE VERSUS PATIENTS ON TREATMENT  
 
 
 
Background:  
A variety of pulmonary manifestations are associated with Rheumatoid 
arthritis; lung disease is the second most common cause of death (18%) 
after infection (27%) in patients with RA. Pulmonary function test 
abnormalities in RA can be restrictive (19-44%) if there  is  pleural  or  
parenchymal  involvement,  or  obstructive  (16-38%)  if  there  is 
obliterative bronchiolitis, bronchiectasis or cricoaryetenoid  arthritis. The 
incidence of pulmonary function test abnormalities in various studies done 
in patients with RA varies widely. 
Objective: 
 
 
1. To assess the proportion of pulmonary function test (PFT) 
abnormalities in patients with rheumatoid arthritis. 
2. To categorize the PFT abnormalities as obstructive or restrictive and 
further quantify them as mild, moderate or severe. 
3. To compare PFT abnormalities between treatment naïve and      
 
  on treatment group. 
 
 
 Methods:  
A pretested semi structured questionnaire was administered to newly 
diagnosed and those patients on treatment for rheumatoid arthritis. They 
underwent routine historical evaluation, physical examination and detailed 
respiratory and musculoskeletal examination. Then they underwent 
pulmonary function testing, chest radiography and pulse oximetry. The 
parameters   recorded   in   spirometry   were   FEV1,   FVC,   PEF and   
FEF25-75%. The spirometer was selected and calibrated in accordance 
with ATS guidelines. The criteria for obstruction and restriction were 
selected in accordance with ATS guidelines 
Results:     
In our study fifty patients were included, 25 newly diagnosed and 25 
patients on treatment for minimum 3 years. The male to female ratio in 
this study was 1:2. The mean age of patients was 46.5±10.5 years. 
Rheumatoid factor was positive in 35 (70%) patients. 16% of patients had 
respiratory symptoms. Incidence of radiological abnormality was 10.7%.  
Fifty patients underwent pulmonary function testing. 56% patients had 
abnormal PFTs 16% had obstructive and 40% had restrictive pattern in 
treatment naive and 64% patient had abnormal PFTs 20% had obstructive 
and 44% had restrictive pattern in on treatment group. 
 The incidence of PFT abnormality in the age group of 50-59 was 
highest. This was not statistically significant.  The number of patients 
with restrictive PFTs increased after three years of disease duration when 
compared with newly diagnosed patients. The number of patients with 
obstructive PFTs also increased when the disease duration was more than 
3 years. No statistical  correlation  was  found  between  the  severity  of  
PFT  abnormality  (both obstruction  and restriction)  and the disease 
duration.  The number of abnormal PFTs increased as the functional 
class of RA increased. 
Interpretation and conclusion: 
 
The number of abnormal PFTs increased as the disease duration increased. 
There was no correlation between the disease duration and the severity of PFT 
abnormality. PFT abnormalities were encountered with greater frequency in 
patients of higher functional class of disability in rheumatoid  arthritis. There 
is increased incidence of PFT abnormality in on treatment group when 
compared to treatment naive group this may be explained by the type of lung 
involvement (ex. If the patient had usual interstitial pneumonia the lung 
disease may progress or remain static) but a longitudinal study is warranted. 
Pulmonary function testing when combined with chest radiography is cost 
effective and a good screening test for early detection of pleuro pulmonary 
involvement in patients with RA. 
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INTRODUCTION 
 
 
Rheumatoid arthritis (RA) is a chronic multi-system disease of 
unknown cause. It is a systemic inflammatory disease and affects 1-2% 
of the general population. The characteristic feature of RA is 
inflammatory synovitis that is persistent and involves most of the 
peripheral joints depending on the duration of disease causing 
cartilaginous and bony erosions. In general population, RA is found in 
0.8% of people and its prevalence increases with advancing age 1.The 
onset of RA is more common in the age group of 40- 50 years 
 
The mortality and morbidity of RA is mostly attributed to its 
extraarticular involvement. Extra-articular manifestations are seen in 
nearly 50% of patients with RA, the commonly affected sites being the 
skin, eye, heart, and lungs4. In 40% of patients the prevalence of 
extraarticular manifestation are so severe clinically. 
 
 
 
 
A wide range of pulmonary manifestations are seen in patients 
with RA. The involvement of lung is the second most common cause of 
death (18%) after infection (27%) in patients with RA 6. In men pleuro- 
pulmonary  manifestations  are  more  common  compared  to  women 7. 
Among  pulmonary  manifestation  Rheumatoid  pleurisy  is  the  most 
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common  intrathoracic  manifestation  of  rheumatoid  arthritis 8.Pleural 
effusion is clinically evident in only 5% of patients with rheumatoid 
 
pleurisy9. 
 
 
 
 
 
Similarly, the incidence of pleural effusion depends on the duration of 
disease. Pleural effusions seen most frequently with longstanding active 
articular disease. These patients also have rheumatoid nodules  10,11. 
Prospective studies using high resolution computed tomography 
 
[HRCT] of the lungs demonstrated that in 20% of patients, there is 
 
 
associated  fibrosing  alveolitis 12.Both  ILD  and  pleural  effusion  can 
precede articular symptoms. 
 
 
 
 
 
Parenchymal involvement in RA may be in the form of rheumatoid 
nodules, Caplan syndrome and interstitial lung disease. The only specific 
pulmonary lesion in these patients were rheumatoid nodules. They are 
single or multiple nodules seen more commonly in males. Similarly 
nodules are common among those with subcutaneous nodules and extra- 
articular manifestations. Caplan’s syndrome is one such seen in silica 
exposed patients with bilateral pulmonary nodules who have rheumatoid 
arthritis. 
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The  incidence of interstitial lung disease [ILD] in RA has been 
found to be19- 44%in a study conducted by Dawson et al It is more 
common in men who are seropositive and aged between 50-60 years of 
age16. 
 
 
RA can affect airways of all diameter and can cause varying disease 
 
 
manifestation17-19. Upper airway involvement includes cricoarytenoid 
arthritis, rheumatoid nodules in the vocal cords and vocal cord paresis. 
 
Lower airway involvement includes bronchiectasis, bronchiolitis with or 
without organizing pneumonia. There is a high incidence of radiographic 
bronchiectasis,  up  to  30%  in  some  HRCT  studies 20-22.Pulmonary 
involvement can be  studied using HRCT   and  DLCO   for anatomical 
 
and physiological abnormalities respectively .However these diagnostic 
tests may not be widely available and cost effective. Pulmonary function 
testing using an office spirometer is a simpler, cheaper and more widely 
available  tool  for  screening  patients  with  RA  for  pulmonary 
involvement. 
 
 
 
Pulmonary function test abnormalities in RA can be restrictive 
(19-44%) if there Is pleural or parenchymal involvement, or obstructive 
(16-38%) if there is obliterative bronchiolitis, bronchiectasis or 
cricoaryetenoid arthritis23. 
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The incidence of pulmonary function test abnormalities in various 
studies done in patients with RA varies widely. 
 
 
 
Although the patients with RA have varying degree of severity in 
the manifestation of pulmonary function, the progression of the disease 
severity may or may not be altered by the immunosuppressive therapy. 
The prognosis in these patients are guarded.The purpose of this study is 
to assess the incidence and type of PFT abnormality in patients with 
rheumatoid arthritis presenting to a tertiary care hospital and also to 
compare PFT abnormalities between treatment naïve and on treatment 
group. 
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AIMS AND OBJECTIVES 
 
 
 
 
 
 
· To assess the proportion of pulmonary function test (PFT) 
abnormalities in patients with rheumatoid arthritis. 
· To  categorize  the  PFT  abnormalities  as  obstructive  or  
restrictive  and further quantify them as mild, moderate or severe. 
 
· To compare the PFT abnormality in treatment naïve and patients 
on treatment for rheumatoid arthritis. 
6  
REVIEW OF LITERATURE 
 
 
 
 
 
Rheumatoid  arthritis  (RA)  is  one  of  the  functionally  disabling 
disease that is common among general population and various    genetic 
and  environmental  contributes  to  its  development.  It  occurs  in 
approximately 1% of the population. The disease is characterized by 
inflammation of synovial membranes and articular structures, which are 
the primary target of the inflammatory process.      Inflammation and 
degeneration along with proliferation of synovial membrane typify the 
disease.  Joint  deformities  and  disability  result  from  the  e rosion  and 
destruction of synovial membranes and articular surfaces 24. 
 
 
RA usually affects the joints in a symmetric manner. The disease 
is polyarticular and involves most of the small joints with exception to 
the  distal  interphalangeal  (DIP)  joints 25. The  joints  most  commonly 
affected  are  Wrists, proximal  interphalangeal,  metacarpophalangeal, 
 
followed by metatarsophalangeal and shoulders. 
 
 
 
 
 
The least commonly affected are the hips and spine. 
Temporomandibular and cervical spine involvement can occur in early 
stage of the disease in certain patients 26.  In patients who have unilateral 
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involvement,  the  other  joints  on  the  same  side  of  the  body  may  be 
affected.  The  arthritis  in  RA  predominantly  involves  peripheral  joints. 
Early wrist and metatarsophalangeal joint involvement is an indicator of 
progression to severe RA26 
 
 
There is also involvement of extra-articular structures in RA. The 
predominant   one   among   this   is   subcutaneous   nodules   and   pleuro- 
pulmonary manifestations. Other organs to be affected are cardiovascular and 
nervous system. Vasculitis and Felty's syndrome are rare manifestations but 
may be severe enough to cause disability 27. The occurrence and course of 
the  extraarticular  manifestations  of  RA  does  not  always  parallel  joint 
 
disease28. Extraarticular manifestations of RA are described in Table1. 
 
 
Most common cause of death in patients with RA includes mostly 
cardiac followed by pulmonary complication. Mortality due to pulmonary 
complications is about 10 to 20% in patients with RA 28,30,31. Although 
pulmonary infection and/ or drug toxicity are frequent complications, lung 
 
disease directly related to underlying RA is more common. The mortality 
ratio  of  patients  with  RA  is  about  2.5  to  5%  when  compared  with 
control28,30. 
 
The majority of lung disease occurs within the first 5years after the 
initial  diagnosis.  In  10  to  20  %  of  patients  it  may  be  the  initial 
manifestation of the disease. The lung parenchyma, any type of airways, 
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pulmonary vasculature  and  pleura  can  all  be  involved, with  variable 
clinical features. [Table2] 
Table1.Extra-articular manifestations  of RA 
 
 
 
 
SITE 
 
 
MANIFESTATIONS 
 
Systemic Fever, Weight Loss, Fatigue, Susceptibility to infection 
 
 
Musculoskeletal 
 
Musclewasting, Bursitis, Tenosynovitis, 
Osteoporosis 
 
Hematological 
 
Anemia, Thrombocytosis, Eosinophilia 
 
Lymphoreticular 
 
Splenomegaly, Felty Syndrome 
 
Cutaneous 
 
Nodules, Ulcers, Sinuses, Fistulae 
 
 
Ocular 
 
Episcleritis, Scleritis, Scleromalacia, 
Keratoconjunctivitis Sicca 
 
Vasculitis 
 
Digital Arteritis, pyoderma Gangrenosum, 
Mononeuritis Multiplex 
 
 
Cardiac 
 
Pericarditis, Myocarditis, Endocarditis, 
Conduction Defects, Coronary 
 
 
Neurological 
 
Cervical Cord Compression, Compressive 
Neuropathies, Peripheral 
 
Pulmonary Nodules, Pleuraleffusions, Fibrosingalveolitis, Bronchiolitis, Caplan Syndrome 
Others Amyloidosis 
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Table2.Pleuropulmonary manifestations  of rheumatoid  arthritis 
 
 
 
SITE MANIFESTATIONS 
 
 
 
 
 
PLEURA 
 
 
Pleuritis, Pleural effusion, 
Empyema 
Pneumothorax 
 
 
 
INTERSTITIUM 
 
 
 
Organizing Pneumonia, Usual interstitial 
Pneumonia 
 
 
 
 
 
AIRWAYS 
 
 
Constrictive Bronchiolitis (bronchiolitis 
Obliterans) 
 
ti 
 
 
VASCULAR 
 
 
 
Pulmonary Hypertension, Pulmonary 
Vasculitis 
 
 
 
OTHER 
 
 
Cricoarytenoid Arthritis, Bullous Lung 
Disease 
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PLEURAL INVOLVEMENT 
 
 
Pleuritis  and pleural effusions: 
 
 
Pleuritic type of chest pain occurs in 25% of patients with RA 32.Five 
percent of patients with RA develop pleural effusions which are small to 
 
moderate, unilateral being more common than bilateral 33.Pleural disease 
is more common in middle aged men. Pleural effusions are more common 
 
in  patients  with  longstanding  active  articular  disease  and  rheumatoid 
 
 
nodules34,35. Rarely , pleural effusion may precede joint disease 36.Small 
effusions usually resolve spontaneously within weeks; however, they 
may  persist  and  present  as  chronic  pleural effusion .Large  effusions 
need therapeutic aspiration and tend to recur after aspiration. 
 
 
 
 
The triad of multinucleated macrophages, large elongated 
macrophages, and under a background of granular debris is characteristic 
of the pleural fluid cytology in rheumatoid effusions 37-39. Pseudochylous 
effusions can also occur with RA35,40. Rheumatoid effusions are usually 
exudative    with   very   low    glucose    levels    and   are    lymphocyte 
 
predominant41. 
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In upto 20% of patients with rheumatoid arthritis and associated 
pleural effusion, prospective studies show fibrosing alveolitis on HRCT. 
Rarely, pneumothorax or pyothorax can occur from ruptured necrotic 
rheumatoid nodule45. 
 
 
The most common pulmonary function abnormality in rheumatoid 
pleural effusion is restriction which worsens when the patient develops 
fibrothorax46. The restriction is associated with paradoxically increased 
 
 
DLCO  which  distinguishes  it  from interstitial  lung  disease  where  the 
 
 
DLCO is reduced. 
 
 
 
 
 
 
 
 
PARENCHYMAL  INVOLVEMENT 
 
 
 
 
 
Pulmonary parenchymal involvement can develop in RA during the 
course of the disease or it may be the initial manifestation occurring in 
very early stages of disease. 
 
 
 
 
Rheumatoid  nodules: 
 
 
The only specific pulmonary lesions observed in patients with 
 
 
RA is pulmonary nodules. Rheumatoid (necrobiotic) nodules are found 
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20% of patients47,48. They are either single or multiple in number usually 
measuring 1-3cm, although nodules measuring upto 10cm may be seen 49. 
Rheumatoid  nodules  are  seen  more  commonly in  males.  Nodules  are 
 
commonly found sub-pleurally in the upper   and Mid zones of the lung; 
rarely they can occur endobronchially. In some case multiple widespread 
nodules are described. 
 
 
 
In Caplan syndrome, pneumoconiosis and RA are synergistic and 
produce as severe fibroblastic reaction with obliterative granulomatous 
fibrosis. Pathologically, the granulomas consist of collections of 
lymphocyte,   macrophages,   plasmacells   and   histiocytes   under   the 
background of necrotic debris. 52. These nodules must be differentiated 
from malignant ones which is done by HRCT and biopsy. These nodules 
 
when subpleural can lead to empyema or pneumothorax on rupture. Other 
complication  is  presenting  as  hemoptysis.  Spirometric  evaluation  in 
rheumatoid nodules is reveals restriction 54. In some patients similar to 
ankylosing   spondylitis   apical   fibrobullous   disease   and   aspiration 
 
pneumonitis can occur. 
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Interstitial Lung Disease: 
 
 
 
 
 
The incidence of ILD in RA has been found to be 19-44% in a study 
conducted by Dawson et al. It occurs more frequently in seropositive men 
aged between 50-60years16. High titres of RF and presence of rheumatoid 
nodules are associated with increased prevalence of pulmonary fibrosis in 
 
RA55,56. 
 
 
 
 
 
Active  or  previous  tobacco  smoking  and  rheumatoid  factor  (RF) 
 
 
seropositivity are risk factors for the development and severity of   ILD in 
 
patients with RA57-60. A correlation has been proposed between the habit 
of  cigarette  smoking  and  the  presence  of  HLA-DRB1"  shared 
epitope"(SE), anticyclic citrullinated peptide antibody(anti- CCP), and the 
 
 
development of  RA61.  The  presence  of  smoking  with  associated  two 
copies  of  the  HLA-DRSE  genes  increased  the  risk  for  RA  21-fold 
compared non smokers with absent gene. 
 
 
 
 
 
In some patients smoking has been independentally associated with 
ILD. Patient with more than 25 pack years have 3.76 % incidence of 95% 
confidence limit. When with RA the incidence increases. 
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The increased reactivity of mesenchymal cells in RA is postulated 
as the cause of pulmonary fibrosis. In this disorder when there is acute 
insult to lung parenchyma, there is activation of fibroblast which causes 
chronic  inflammatory  change  leading  to  the  endpoint  of  pulmonary 
fibrosis and tissue destruction66. 
 
Modes of presentation of RA associated ILD: 
 
 
 
 
 
1.  ILD  may  be  incidentally  detected  on  chest  radiograph  or  abnormal 
screening spirometry in an aymptomatic patient with RA. 
 
 
 
2. Diagnosis may occur during screening for high-risk occupational exposure, 
such as asbestosis. 
 
 
 
3. Clinically overt disease may present insidiously and progress slowly 
[chronic ILD]. It may also present acutely,sub-acutely or have a relapsing 
remitting course. Disorders with chronic, insidious,and slowly progressive 
courses are those that most resemble IPF and usually share a   common 
pathology (ie,UIP). Pulmonary fibrosis in RA can occur as a side effect of 
certain         disease         modifying         agents         [eg.,methotrexate]. 
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Cryptogenic organizing pneumonia[COP]: 
 
 
 
 
 
 
Cryptogenic  Organising  pneumonia  is  seen  more  common  in 
rheumatoid arthritis when compared to other connective tissue 
disorders67.It usually involves terminal bronchioles and distal air spaces. It 
is characterized by presence of plugs of granulation  tissue in the airspaces. 
 
The main pathophysiology of COP is lymphocytic infiltration within 
bronchiolar walls and surrounding interstitium it usually shows multifocal 
consolidation on computed tomography when compared to bronchiolitis 
obliterans          PFT  shows  restrictive  pattern. 68.  It  responds  better  to 
corticosteroids.    The clinical presentation of COP initially is similar to a 
 
flu like illness, which is gradually progressive in nature. It takes weeks or 
months  to  develop  a  full  blown  disease  characterized  by  dyspnea  or 
exercise intolerance. The disease course may vary from spontaneous 
remission to progressive disorder. Steroids are the mainstay of therapy and 
disease may reccur on withdrawal of drug. Some patients may progress to 
end-stage fibrotic lung disease. 
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Acute Interstitial pneumonia: 
 
 
 
 
 
Occasionally  ILD  in  RA  can  present  acutely.  The  most  common 
pattern  with  this  presentation  is  AIP.  It  is  an  idiopathic  form of  lung 
disease  which  is  more  severe  in  presentation.  It  has  a  similar 
histopathology as that of       adult respiratory distress syndrome (ARDS) 
with diffuse alveolar damage(DAD). These patients usually have no no 
antecedent history. These patients progress rapidly to respiratory failure. 
These patients does not respond to any treatment steroids or 
immunosuppressive therapy. Clinical finding is similar to idiopathic 
pulmonary fibrosis. They are usually cyanotic with fine end-inspiratory 
pulmonary rales (Velcro rales). .Digital clubbing may accompany many of 
these  disorders.  They  may present  with  right  heart  failure  in  advanced 
cases. Of all the histological patterns of ILD, the non specific interstitial 
pattern is the most prevalent69although in one study, most common pattern 
is usual interstitial pneumonia. 
 
 
 
 
Usually the  prognosis of interstitial lung disease in RA is good. 
There is slow deterioration of lung function in RA associated ILD. 
“However, one study reported a median survival of 3.5years and a 5-year 
survival rate of 39% in 49 patients with RA hospitalized for interstitial 
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pulmonary fibrosis, survival very similar to what is observed in patients 
 
 
with  idiopathic pulmonary fibrosis 71.The investigation of choice to detect 
interstitial pneumonia  is HRCT. It is abnormal in upto 80% of patients The 
prevalence of radiological evidence of pulmonary fibrosis in patients who 
 
 
have rheumatoid arthritis ranges from 2-10% 72. The most representative 
data has come from a study in which chest radiographs of 309 patients who 
 
have rheumatoid disease were compared with those of age and sex matched 
 
 
controls73.In this study a reticulonodular pattern consistent with fibrosis 
was  seen  in  4.5%  of  patients  with  rheumatoid  disease  v/s  0.3%  of 
 
controls.The pattern and distribution of fibrosis on both CXR and HRCT 
are indistinguishable from those of IPF. In early stage, the radiographic 
appearance consists of irregular linear opacities causing a fine reticular or 
reticulonodular pattern74. The abnormality usually involves the lower lung 
zones75. 
 
 
 
 
Pulmonary function tests(PFTs) with the diffusing capacity of the 
lung  for  carbon  monoxide  (DLCO)  are  sensitive  tests  to  detect  RA 
associated 
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ILD. Evidence of restriction on lung function testing is found in 30- 
 
 
40% of all patients with RA associated ILD77.The important functional 
defect  is  impairment  of  alveolo-capillary  gas  exchange  with  reduced 
diffusion capacity best measured utilizing single breath carbon monoxide 
diffusion capacity. Even though the prevalence of a restrictive defect in 
consecutive  patients  was  not  high  (5-15%) 78-81  reduced  DLCO  was 
observed in more than 50% of patients with rheumatoid arthritis 82,84 and 
reduced DLCO was suggested to be the most sensitive marker of interstitial 
 
pneumonia on high-resolution computed tomography (HRCT). 
 
 
 
 
 
In a study conducted by Laitinen O et al, vital capacity (VC) and 
single-breath diffusing capacity for carbon monoxide of the lungs (DLCO) 
were measured and chest X-ray evaluated in 129 patients with rheumatoid 
arthritis (RA)83.Findings in the123 cases were observed as follows : in one 
of  the  lung  function  tests  or  X-ray examinations  ,  35%;  abnormal  X- 
 
rays,18%; reduced VC or Dco , 28% ; simultaneously low VC and Dco, 
 
 
7%;  and  pathological  findings  in  all  three  tests,  2%.The  patients  with 
abnormal X-rays showed extremely low VC and Dco values .Changes in 
respiratory function involved restrictive impairment and diffusion defects, 
and  the  results  further  implied  that  restrictive  changes  develop  early, 
whereas decreased diffusion capacity is associated with more advanced 
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rheumatoid lung .The disparity abnormal findings in chest radiographic 
changes and lung function tests suggests that, both radiographic methods 
and pulmonary   function tests should be used for evaluating pulmonary 
manifestations in patients with RA. 
 
 
 
In a study by Gabbay et al in 1997,abnormalities consistent with ILD 
were found in one or more investigation in 58% of patients with RA.(PFT 
in 22%,DTPA nuclear scaning 15%, HRCT in 33% and chest radiograph in 
6%.Hence,PFT was a sensitive measure in picking up pulmonary 
abnormalities85 
 
 
 
Fibrosing alveolitis is a common serious complication of RA. In a 
study  conducted  by  Dawson  et  al,19%  had  fibrosing  alveolitis  ;most 
frequently reticular pattern on HRCT, 14% had restrictive PFT 16       A 
 
 
distinctive manifestation of rheumatoid lung disease is progressive upper 
lobe  fibrosis  and  cavitation  .Patients  with  this  disease  may be 
asymptomatic and present only as a radiological abnormality. 
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AIRWAY DISEASE IN RA: 
 
 
RA can cause upper, lower, and small, distal airway disease 17-19. 
 
 
Upper airway disease: 
 
 
Cricoarytenoid arthritis is a frequent manifestation of RA that presents 
with symptoms of foreign body sensation in throat, soreness, and throat pain 
which radiates to the ears. Some patients may present with dysphonia, 
dysphagia and stridor. In a study conducted by Hayakawa.H et   al, nearly 
26%of  patients  with  RA  had  cricoaryetenoid  arthritis 86. Usually  the 
clinically diagnosis is based on direct or indirect laryngoscopy. The finding 
 
includes  inflammatory  changes  of  the  arytenoids  with  reduced  motility. 
Diagnosis is usually confirmed by CT 
 
 
 
 
In some cases, ankylosis of the cricoarytenoid joint may induce an 
upper airway obstruction with a characteristic pattern on the flow-volume 
curve. In these patients with dyspnea, surgery is indicated to treat ankylosis. 
Some patients are predisposed to obstructive sleep apnea syndrome 
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Small airway disease: 
 
 
Small  airway  disease  with  physiologic  obstruction  is  common 87. 
And these patients usually have non productive cough, dyspnea on exertion 
or wheezing. The diagnosis is made by HRCT. It usually shows involvement 
of small airway  with  centrilobular nodules, heterogenous air trapping and 
hyperinflation.  Pathologically,  both  fibrosing  (obliterative  or  constrictive 
bronchiolitis) and cellular (diffuse panbronchiolitis and follicular 
bronchiolitis) have been well described 88. 
“Controlled studies of lung function in patients with RA demonstrate 
an increased prevalence of chronic airway obstruction (16–38%) 89 and 
 
 
increased bronchial reactivity to methacholine (55%). In a PFT survey of 
patients with rheumatoid arthritis, airway obstruction was observed in9- 
37%, even in non-smoking patients 90. In PFT, constrictive bronchiolitis 
 
 
manifests as severe irreversible airway obstruction with hyperinflation.  
 
 
 
 
 
Obliterative bronchiolitis: 
 
 
 
 
 
It is a progressive condition and death from respiratory failure occurs 
in 2-3years of onset. Histologically the lesion demonstrates bronchiolar 
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wall destruction with effacement of lumen by granulation tissue     and 
eventual replacement of bronchiolar wall by fibrous tissue. The histologic 
picture is usually preceded by exudation of inflammatory substrates. The 
progression of this disease is heterogeneous. It is more in patients having 
indolent disease. The prevalence of unsuspected OB is uncertain.    Patients 
may  benefit  from  treatment  with  inhaled  corticosteroids  and 
bronchodilators.  In  50%  of  patients  the prognosis  is  poor.  PFT  shows 
severe airflow obstruction with reduced DLCO. Pencillamine use has been 
related to this condition 92. 
 
 
 
 
Follicular  bronchiolitis: 
 
 
Follicular bronchiolitis is characterized by external compression of 
bronchioles by hyperplastic lymphoid follicles with variable lymphocytic 
infiltration of the bronchiolar wall. FB is more commonly seen in RA 
compared to other connective tissue disorders. It is unclear if follicular 
bronchiolitis predisposes to OB. Isolated FB simulates ILD with reticular 
or reticulonodular abnormalities on CXR. The PFT abnormality may be 
Restrictive  or  obstructive93.     It  is  more  responsive  to  corticosteroid 
therapy. 
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Lower airway disease: 
 
 
 
 
 
Bronchiectasis  is  a  common  manifestation  of  RA  .Clinically 
significant bronchiectasis is less frequent and involving 1–5% of Patients 
with RA. Bronchiectasis is more common in women than in men (male to 
female ratio of 1:2.8) 
 
 
 
In some studies, RA appears at a younger age in patients with 
bronchiectasis (46vs51 years).Symptoms are identical to other causes of 
bronchiectasis and include cough, sputum production, frequent episodes of 
infection, and hemoptysis. The co-existence of RA and bronchiectasis is 
associated  with  an  alteration  of  lung  function  tests  and  a  poor  5-year 
survival .In most patients (90%), bronchiectasis precedes the development 
of RA by 25–30years .HRCT studies demonstrate that 20–35% of patients 
with RA have bronchiectasis (associated with interstitial changes in one- 
third of the cases)94. 
 
 
However, clinically significant disease is much less frequent. 
Secondary development of bronchiectasis after 7–10years of evolution of 
RA is possible. 
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In a case–control study, patients with RA and bronchiectasis were 7.3 times 
more likely to die than the general population,5.0 times more likely than 
patients   with   RA   and   2.4   times   more   likely   than   patients   with 
bronchiectasis without RA. An increased risk of death within the RA and 
bronchiectasis group was associated with a history of smoking, moresevere 
RA and steroid usage. In this study, 60% of the mortality was due to 
infections               and               acute               respiratory               failure. 
 
 
 
Bronchiectasis is one of the predisposing factor to lung infections. It 
also increases the postoperative morbidity in patients with RA. The 
pathogenesis of bronchiectasis is poorly understood. These patients usually 
have decreased humoral immunity which may be the reason for increased 
risk of infection. Some patients with RA have recurrent bronchial infection, 
lymphedema , pleural effusions and typical nail changes which constitutes 
yellow nail syndrome. 
 
 
 
VASCULAR INVOLVEMENT: 
 
 
 
 
 
The involvement of lung vasculature is rare in RA. It presents as 
pulmonary hypertension. Some patients have alveolar hemorrhage 
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secondary to pulmonary vasculitis. This presentation is correlated with the 
presence of antineutrophil cytoplasmic antibodies 95. 
 
 
DRUG INDUCED LUNG DISEASE 
 
 
Several drugs used for the treatment of RA have been associated with 
drug-induced lung disease. Methotrexate, goldsalts, D-penicillamine ,and 
nonsteroidal anti- inflammatory drugs are associated with repiratory adverse 
effects97. Two percent of patients with RA develop  an acute respiratory 
infection  requiring hospitalization annually. Pneumonitis as a consequence 
 
of treatment with methotrexate is now a frequent feature as the use of this 
agent increases. “The reported incidence of methotrexate pneumonitis in RA 
varies from 0.86% to 6.9%98” .The risk is maximal in the first year of 
treatment. Mortality from methotrexate pneumonitis is around 20% in most 
 
series99. 
 
 
 
 
 
 
Patients with underlying lung disease and who are smokers are at 
increased risk for pneumonitis. It is important to diagnose    patients with 
prior predisposing condition so that it may help in alternative treatment 
regimen. The single most predictive test helpful to identify the risk for 
pneumonitis is reduced gas transfer ratio. .Patients on methotrexate are at 
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lesser risk of developing infection than who are not on the drug. The major 
cause of death is failure to mount immune response in this patients. 
 
A survey from Japan reports an increased risk of acute pneumonitis 
in leflunomide treated patients with an incidence of 0.5% 100. In Indian 
 
 
studies, there is no evidence that combination of leflunomide with 
methotrexate increases the risk of pneumonitis beyond that which 
methotrexate itself carries. 
 
 
 
 
Infliximab infusions administered for active articular disease have 
caused acceleration of underlying rheumatoid interstitial  lung  disease  in 
few patients101. Recent  data    on  patients  receiving  etanercept  for  RA 
 
 
indicate that this agent can potentiate an acute pneumonitis with ground 
glass shadowing on HRCT and histological  evidence    of   granulomatous 
pneumonitis. 
 
 
 
 
This is distinct   from Methotrexate pneumonitis and is almost 
exclusively confined to patients with prior significant lung disease, patients 
with interstitial damage faring less well than those with airway disease. 
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CLINICAL  STUDIES–PULMONARY INVOLVEMENT IN RA 
 
 
 
 
 
In a study conducted in 1997 by Cortet-Bernardet, sixty eight patients 
(54   women,14men),   a   significant   decrease   of   FEV1/FVC,   FEF25%, 
FEF50%,  FEF75%,  FEF25-75%,  and  TLCO  was  observed(p<0.05)  and 
13.2% of the patients had a small airways involvement defined by a decrease 
 
 
of FEF25-75% below 1.64SD102. The most frequent HRCT findings were: 
 
 
bronchiectasis(30.5%), pulmonary nodules (28%), and air trapping(25%). 
 
 
 
 
 
The patients with small airways involvement had a high frequency of 
recurrent bronchitis (75%v34%,p=0.05) and bronchiectasis(71% v23%, 
p=0.019). The patients with bronchiectasis had low values of FEV 1, FVC, 
FEF25-75%, and TLCO (p<0.01). This study suggests a significant 
association between small airways involvement on PFT and bronchiectasis 
on HRCT in asymptomatic patients with RA. 
 
 
In a study conducted in 2004 by Terasakietal, PFT and HRCT were 
done in 34 patients103. Bronchial wall thickening was detected in 85%, 
 
 
small  nodules  in  71%  and  bronchial  dilatation  in  62%.  The  extent  of 
bronchial wall thickening correlated with MMEF, FEF75 and FEF50. 
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In another study conducted in 1998 by Perez et al where 50 patients 
with   RA   (9malesand41females),   included   39   non-smokers   and   11 
smokers104. Airway obstruction (reduced FEV1/FVC) was found in 18% 
 
 
of patients. Small airway disease, reflected by reduced FEF25-75 was seen 
in  8%  of  patients.  The  airway  obstruction  and  small  airway  disease 
correlated   well   with   the   presence   of   bronchiectasis,   bronchial   wall 
thickening and with bronchial infection on HRCT. 
 
 
 
 
A study was conducted in 2004 by Doyle et al to determine the 
prevalence   of   airway   hyperreactivity(AHR)   in   patients   with   newly 
diagnosed   rheumatoid   arthritis   (RA)who   had   received   no   disease- 
modifying   anti-rheumatic   drugs   (DMARD)   and   to   characterize   the 
spectrum of  lung  diseases  identifiable  in  these  patients  at  the  time  of 
presentation105.The pulmonary abnormalities included two  patients with 
hypoxia   (12%),   2withobstruction   (12%),   3withrestriction(18%)   and 
 
4withAHR(23%). Their data also suggested a strong association between 
pulmonary diseases in RA and cigarette smoking. Although no single 
characteristic   lung   disease  such  as  AHR  was  identified  in  patients 
presenting with RA, the association between pulmonary. Involvement in 
RA and cigarette smoking is striking. 
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A study was conducted by Vergnenegre et al in 1997, to assess the 
percentage of respiratory disorders and airway obstruction in patients with 
rheumatoid arthritis. They compared lung function test results between 
patients with rheumatoid arthritis and control subjects with other 
rheumatological conditions 90. 
 
 
A prospective case-control study of respiratory symptoms and lung 
function abnormalities was performed in a series of 100 patients with 
rheumatoid arthritis. Eighty eight patients with other rheumatological 
diseases served as controls. Diagnosis of respiratory disorders was based 
on clinical, radiological and spirometric findings. Airway obstruction was 
determined from predicted values. The number of symptoms, respiratory 
disorders (including bronchiectasis) and lung function abnormalities was 
higher in patients with rheumatoid arthritis than in controls. 
 
 
 
In a study conducted by Radoux.V.etal, after excluding smokers, the 
proportion of airway obstruction  in patients with rheumatoid arthritis was 
16% (versus0%incontrols), although the patients with rheumatoid arthritis 
still had more symptoms and respiratory disorders 88. 
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The Chi-squared test did not identify an relationship between airway 
obstruction, duration of  rheumatoid  arthritis  and type of  treatment. The 
study concluded that respiratory disorders (including bronchiectasis) and 
airway obstruction are more frequent among patients with rheumatoid 
arthritis than in rheumatological controls. 
 
 
 
In a study by Fuld et al in 2003, a longitudinal study of pulmonary 
function in asymptomatic, non-smoking patients with active RA requiring 
DMARD(19), 134 temporal change  in lung function was looked for  that 
would predict subsequent development of PFT abnormality or respiratory 
symptoms106.  The  prevalence  of  PFT  abnormality  was  higher  than 
expected when compared with the reference population but there was no 
 
significant  increase  in  number  over  10  years  (8.7%in1990and  8.8% 
in2000). Reduced DLCO and increased         RV/TLC were the only 
abnormalities to develop over study period. Rates of change of pulmonary 
function variables were not significantly different from zero. 
 
 
 
EVALUATION 
 
 
RA-ILD is usually when RA patient   develops dyspnea, cough, 
auscultatory  crackles,  or  abnormalities  on  pulmonary  function  testing 
(PFTs) or chest radiograph. The evaluation of suspected RA-ILD typically 
30
31  
includes a combination of laboratory testing, PFTs, imaging, and sometimes 
bronchoalveolar lavage or lung biopsy. These tests are designed to 
characterize the presence, pattern, and severity of ILD, and also to exclude 
differential diagnoses. 
 
 
 
 
 
A key component of the evaluation is determination of the type of 
ILD, as all of the histopathologic types of idiopathic interstitial lung disease 
can occur in the context of RA . Often the cause and type of ILD can be 
determined by the combination of clinical presentation, PFTs, and HRCT. 
In a minority of cases, when these features are not typical for a given type 
of ILD and the patient is symptomatic, fit for surgery, and the biopsy would 
change  the  therapeutic  approach  ,  characterization  of  the  ILD  by  lung 
biopsy is often appropriate . 
 
 
 
 
 
It is important to determine whether the patient is experiencing a first 
presentation of new interstitial disease, an exacerbation of previously 
unknown   interstitial   disease   (usually  UIP   pattern),   or   one   of   these 
possibilities combined with a superimposed comorbid disease not directly 
due to RA. Investigations evaluating the various pulmonary manifestations 
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of RA are designed to exclude the possibility that another lung disease or 
extra-pulmonary process is etiologic, such as: 
 
●Infection 
 
 
●Drug-induced lung 
 
 
●Hypersensitivity pneumonitis due to inhalational 
 
 
●A  new  or  intercurrent  ILD,  such  as  acute  interstitial  pneumonitis  or 
vasculitis, if symptoms are rapidly progressive 
●Heart failure, pulmonary embolism, cancer, or recurrent gastroesophageal 
aspiration 
 
 
 
 
Laboratory testing — 
 
 
For patients with (or without) RA who present with diffuse lung 
disease, we generally obtain a complete cell count and differential to look 
for leukocytosis (infection), leukopenia (immune suppression due to 
medication), or eosinophilia (possible drug reaction). A serum natriuretic 
peptide level is measured to screen for heart failure or pulmonary 
hypertension.   Most   patients   have   already   had   serologic   testing   for 
rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies 
(ACPA), but full assessment of other autoantibodies should be performed, 
including antinuclear antibodies and anti-double stranded DNA antibodies, 
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and also cryoglobulins to assess for co-existent rheumatic disease that may 
be contributory in the appropriate clinical setting, such as when purpura, 
Raynaud phenomenon, skin ulcers, or renal disease are present. 
 
 
 
 
 
Rheumatoid factor may be present in high titer in patients with ILD . 
ACPA positivity also correlates with the presence of RA-ILD and higher 
titers of ACPA may be associated with more severe ILD . 
 
 
 
 
 
While the sedimentation rate (ESR) and C-reactive protein (CRP) 
correlate with activity of RA joint disease, their role in the evaluation of 
lung disease is unclear. 
 
Pulmonary function tests : 
 
 
Complete lung function testing (spirometry, lung volumes, diffusing 
capacity) and pulse oximetry are obtained in all patients with suspected ILD 
to assess the pattern, severity, and progression of respiratory       impairment. 
 
Abnormalities associated with ILD include reductions in lung volumes and 
diffusing capacity for carbon monoxide , oxygen desaturation during 
exercise, and in late disease, resting hypoxemia. In a study of 81 patients 
with recent onset rheumatoid arthritis, for example, 33 percent had a DLCO 
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<80 percent of predicted, while only 14 percent had symptoms . When 
assessing changes over time, changes that are considered clinically important 
include a decrease in forced vital capacity of ≥10 percent or a decrease in 
DLCO of ≥15 percent. 
 
Among patients with RA, restrictive abnormalities on pulmonary 
function tests are common even in the absence of symptoms and may reflect 
poor muscle strength or kyphosis due to osteoporosis rather than ILD. The 
association of restrictive abnormalities and evidence of abnormal gas 
exchange (eg, reduced DLCO, low pulse oxygen saturation) favor the 
diagnosis of ILD. 
 
Arterial blood gases are obtained to corroborate abnormal pulse oxygen 
saturation or DLCO findings. 
 
 
 
 
 
Imaging studies — 
 
 
In patients with RA, a chest radiograph is typically obtained to assess 
complaints of dyspnea or abnormal findings on lung examination. Further 
imaging depends on the chest radiograph findings and severity of symptoms. 
 
●Chest radiograph – 
 
 
The chest radiograph may be normal in patients with early or mild 
 
 
RA-ILD. When abnormal, potential findings include bibasilar ground glass 
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opacities, reticular and nodular opacities, and honeycombing. Late in the 
course of the disease, changes suggestive of pulmonary hypertension (eg, 
enlargement of central pulmonary arteries, attenuation of peripheral vessels) 
may be detectable 
 
 
 
 
●High resolution computed tomography – 
 
 
 
 
 
High resolution computed tomography (HRCT) is obtained in almost all 
patients with symptoms, PFT findings, or chest radiograph abnormalities 
suggestive of diffuse parenchymal disease. Both prone and supine views are 
obtained   to   avoid   misinterpretation   of   gravity-induced   opacities   in 
dependent areas. HRCT detects abnormalities earlier than chest radiography 
and may reveal a range of parenchymal abnormalities . In one study of 20 
non-smoking patients with RA and normal chest radiographs, five patients 
had basilar bronchiectasis and one had mild ILD by HRCT . In a review of 
84  patients  with  longstanding  RA,  29  percent  of  asymptomatic  and  69 
percent  of  symptomatic  patients  had  abnormalities  on  HRCT.  These 
findings  included  bronchiectasis  or  bronchiolectasis  in  the  absence  of 
fibrosis (19 percent); ground glass attenuation (14 percent); nonseptal linear 
attenuation (18 percent); and honeycombing (10 percent). In general, the 
HRCT  findings  accurately  predict  the  pathologic  findingsHRCT  can 
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distinguish a predominantly ground glass pattern from reticular changes and 
honeycombing, which is helpful in differentiating among the various types 
of ILD. As examples: 
 
 
 
 
•Ground glass opacification is consistent nonspecific interstitial pneumonia 
(NSIP),  acute  interstitial  pneumonia,  and  desquamative  interstitial 
pneumonia (DIP). 
 
 
 
 
•Reticular  changes,  traction  bronchiectasis,  and  honeycombing  are  more 
typical of usual interstitial pneumonia (UIP) . Infrequently, however, the 
HRCT may suggest UIP, but NSIP will be identified by biopsy •Persistent 
areas  of  subpleural  consolidation  are  more  suggestive  of  organizing 
pneumonia [7]. 
 
 
 
 
Review of previously performed CT images, including abdominal CTs with 
views that include the lung bases, may identify a pre-existing ILD. In 
addition, review of older images can help determine the rate of progression 
of  ILD  and  whether  the  timing  of  changes  in  CT  findings  over  time 
correlates with symptoms or medication usage. 
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●Nuclear imaging – 
 
 
 
 
 
Nuclear imaging with gallium and technetium-99m  diethylene 
 
 
triamine penta-acetic acid (Tc-99m DTPA) may be abnormal in RA-ILD. 
However, the role of these studies in diagnosis or prognosis of RA-ILD has 
not been defined. 
Bronchoalveolar lavage — 
 
 
The main role for bronchoalveolar lavage (BAL) in patients with an 
acute  onset  of  respiratory  symptoms  or  fever  and  radiographic 
abnormalities is to exclude diffuse lung diseases other than RA-ILD, such 
as acute eosinophilic pneumonia, alveolar hemorrhage, malignancy, or 
opportunistic or atypical infection. BAL is frequently abnormal in patients 
with RA-ILD, but the findings are nonspecific. 
 
Abnormalities in cellular constituents and mediators found on BAL are 
not useful for differentiating among the types of RA-ILD or predicting 
prognosis or response to therapy. As a result, BAL is not considered to be a 
routine part of the diagnostic approach to RA-ILD. The following BAL 
findings have been reported from research studies: 
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●In patients with clinical evidence of RA-ILD, total cells, neutrophils, and 
occasionally eosinophils are elevated . 
 
 
 
 
●In  the  absence  of  symptoms,  lymphocytosis  is  more  common  .  This 
finding may be associated with a better prognosis, as evidenced by the 
subclinical nature of the lung disease. 
 
 
 
 
●Increases in the production of tumor necrosis factor (TNF) alpha by 
macrophages   and   the   levels   of   superoxide   anion,   fibronectin,   and 
collagenase activity in BAL have been noted in patients with RA-ILD . 
 
 
 
 
Lung biopsy — 
 
 
 
 
 
 
As HRCT patterns have been found to correlate reasonably closely 
with ILD histopathologic patterns, lung biopsy is rarely required in most 
patients with RA-ILD. However, when the results of the above evaluation 
do not allow the clinician to make a confident diagnosis of a given type of 
ILD    (eg,    UIP)    and    the    patient’s    lung    disease    is    clinically 
significant and/or progressing, lung biopsy with careful examination of lung 
tissue  is   appropriate.  A   transbronchial  biopsy  obtained  via  flexible 
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bronchoscopy  is  usually  inadequate  for  diagnosis,  so  lung  biopsy  is 
typically performed by either video-assisted thoracoscopy (VATS) or open 
thoracotomy.   The   decision   about   whether   a   lung   biopsy  should   be 
performed should be made on a case-by-case basis, taking into account the 
patient's clinical condition and the impact of the results on the patient's 
management. As an example, lung biopsy may be warranted in younger 
patients in whom lung transplantation might be considered eventually. 
 
 
 
 
 
Serum markers — 
 
 
No serum markers have demonstrated clinical utility for the diagnosis 
of RA-associated ILD, although some may be promising. Increased serum 
concentrations  of  KL-6,  a  glycoprotein  found  predominantly  on  type  II 
pneumocytes and alveolar macrophages, have been reported in patients with 
interstitial pneumonia . As an example, one study assessed the potential role 
of serum KL-6 for the diagnosis of ILD associated with systemic 
inflammatory  disorders  in  57  patients,  22  of  whom  had  known  ILD  . 
Patients with ILD had significantly higher KL-6 values than those without 
lung disease, with the sensitivity and specificity ILD estimated at 61 and 99 
percent, respectively, in this selected population. Measurement of serum 
KL-6 remains a research tool at present, but may become clinically useful 
in the future if the high specificity of the test is confirmed. 
Another  report  noted  that  serum  anti-interleukin-1-alpha  antibody 
titers were significantly higher in patients with RA and ILD, in comparison 
to patients with RA, but not ILD, and to controls. Higher titers were 
associated with higher serum lactic dehydrogenase (LDH) concentrations 
and larger alveolar to arterial oxygen gradients . 
 
In a case series (58 patients with RA-ILD; 27 with RA but no ILD), 
serum antibodies to citrullinated Hsp90 appeared specific (>95 percent), 
although  not  sensitive  for  RA-ILD  .  Anti-citrullinated  Hsp90  antibodies 
were not found in 41 patients with mixed connective tissue disease or 33 
patients with idiopathic pulmonary fibrosis, further suggesting specificity. 
The  role  of  these  autoantibodies  to  citrullinated-Hsp90  in  identifying 
patients  with  RA-associated  ILD  needs  validation  in  other  groups  of 
patients with RA. In a separate study, a stronger association was observed 
between the number of anti-citrullinated peptide antibodies (ACPA) and 
radiographic usual interstitial pneumonia than with non-specific interstitial 
pneumonia  .  If  confirmed  this  would  be  a  very  useful  test  to  help 
distinguish between these two entities. 
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DIAGNOSIS — 
 
 
The diagnosis of RA-ILD is generally based on the combination of 
compatible  clinical  features,  pulmonary  function  testing  (eg,  restrictive 
changes and a gas transfer abnormality), and high resolution computed 
tomography (HRCT) findings (eg, reticular, ground glass, or consolidative 
changes), and also exclusion of other processes, such as infection, drug- 
induced pulmonary toxicity, and malignancy. 
 
Determination of the underlying pattern of RA-ILD may be based on a 
typical HRCT pattern or on lung biopsy findings. 
 
 
 
 
 
DIFFERENTIAL DIAGNOSIS — 
 
 
In patients with RA, the differential diagnosis of diffuse lung disease 
includes drug-induced lung toxicity, opportunistic infection, heart failure, 
recurrent aspiration, malignancy, and other inflammatory causes of ILD. In 
addition, patients presenting with new respiratory symptoms with evidence 
of ILD may have an exacerbation of previously unknown ILD. In the latter 
situation, obtaining old computed tomography images, even if performed for 
an abdominal problem, may provide clues to pre-existing disease. 
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●Drug-induced lung toxicity – 
 
 
 
 
 
Drug-induced lung toxicity has been associated with most of the 
medications used to treat RA, including the nonsteroidal anti-inflammatory 
drugs           (NSAIDs) , methotrexate , leflunamide , gold, penicillinamine, 
and biologic agents (eg, tumor necrosis factor inhibitors tocilizumab , 
rituximab)  .  Toxicity  has  rarely  been  reported  with anakindra and  not 
with abatacept. Also, no reports of drug-induced ILD have been published 
since approval of the Janus kinase (JAK) enzyme inhibitor tofacinib for use 
in RA. An essential step in the evaluation of possible drug-induced lung 
toxicity   is   to   stop   any   implicated   medication(s)   and   observe   for 
improvement over the next few days to weeks. 
 
 
 
 
Development of a sarcoid-like reaction in the lungs has been reported 
with infliximab , adalimumab , entanarcept and appears to be a class effect 
of anti-tumor necrosis factor-alpha (anti-TNF-alpha) agents . 
 
 
 
 
Patients may present with dry cough, night sweats, and weight loss . 
Onset of disease ranges from 1 to 50 months after initiation of the anti-TNF 
agent . Sarcoid-like granulomas have also been reported in the skin, lymph 
nodes, and bone marrow in association with anti-TNF-alpha agents. In one 
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series, the serum angiotensin converting enzyme level was elevated in 48 
percent   .   Cessation   of   the   anti-TNF-alpha   agent   generally  leads   to 
resolution of the granulomas over several months . Recurrences have been 
reported when the same anti-TNF-alpha agent is resumed, but appears less 
common when an alternate agent is used . 
 
 
 
 
●Opportunistic infection – 
 
 
Opportunistic infections are well-known complications of 
immunosuppressive therapies used to treat RA. The diagnosis of 
opportunistic  infection  typically  requires  special  stains  and  culture  of 
induced          sputum and/or bronchoalveolar          lavage          specimens. 
 
 
 
Pneumocystis (jirovecii) pneumonia (PCP) is associated with all of the 
immunosuppressive agents, particularly when the patient is receiving a 
glucocorticoid dose equivalent to ≥20 mg of prednisonedaily for one month 
or longer in addition to a second immunosuppressive agent or taking an 
anti-TNF-alpha agent in combination with other intensive 
immunosuppression. PCP should be in the differential of new, recent onset 
dyspnea, fever, and diffuse of patchy radiographic disease. 
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Anti-TNF-alpha agents also increase the risk for new and reactivation 
of latent fungal infections, such as histoplasmosis, coccidioidomycosis, 
cryptococcosis, and other invasive fungal infections. 
Mycobacterial disease (both tuberculous and nontuberculous) is well- 
described complication of anti-TNF-alpha agents. 
 
 
 
 
●Hypersensitivity pneumonitis – 
 
 
The clinical, imaging, and histopathologic characteristics of chronic 
hypersensitivity pneumonitis are similar to those of the UIP pattern of RA- 
ILD. The radiographic findings typical of subacute hypersensitivity 
pneumonitis (eg, diffuse micronodules, ground glass attenuation) are also 
seen in some patients with RA and organizing pneumonia. 
 
 
 
 
●Other causes – 
 
 
Heart failure is generally excluded based on physical examination, 
natriuretic          peptide          measurement,          and          echocardiogram. 
Recurrent  aspiration  typically  affects  the  lower  lobes;  swallowing 
difficulties provide a clue to the diagnosis, although they are not always 
present. 
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The optimal treatment for RA-ILD has not been determined, but 
generally parallels the treatments that have been used for the underlying 
type of interstitial pneumonia, whether that pattern is diagnosed by lung 
biopsy or presumed based on clinical presentation and high resolution 
computed tomography (HRCT). Certainly patients who are current cigarette 
smokers should be encouraged to stop smoking. Case series and clinical 
experience suggest a benefit to systemic glucocorticoids and 
immunosuppressive agents in selected patients . 
 
 
 
 
 
As with the idiopathic interstitial pneumonias, the decision to treat the 
various histopathologic forms of RA-ILD needs to weigh prognosis, 
likelihood of response to therapy, and potential benefits of early therapy (ie, 
before fibrosis is established) against the potentially significant adverse 
effects of treatment (eg, uncontrolled diabetes, immunosuppression, 
osteoporosis). Abnormalities in any single pulmonary function test are 
common in patients with RA. Thus, the diagnosis of clinically significant 
disease that warrants further monitoring or treatment is based upon the 
severity of impairment, rate of progression, and pattern of abnormalities 
identified by the investigations described above, rather than results of a 
single test. 
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As  a  way  to  guide  treatment  and  monitoring  strategies,  a  newer 
approach used in guidelines for idiopathic interstitial pneumonias has been 
to categorize the disease behavior as self-limited, reversible, stable, 
progressive, or irreversible, with or without the potential for long-term 
stabilization with therapy. This means that predictors of survival, such as a 
low diffusing capacity and extensive fibrosis on the HRCT, linked with 
observed rate of progression may better guide treatment in the face of 
infrequent  pathological  confirmation,  heterogeneous  outcomes,  and  little 
data to guide treatment other than clinical behavior 
 
 
Patients who can be monitored without specific treatment — 
Asymptomatic patients and those with mild RA-ILD are monitored 
 
 
with clinical assessment, pulmonary function tests (PFTs), and a chest 
radiograph at six to twelve month intervals, or sooner if symptoms worsen. 
Similarly, patients with a usual interstitial pneumonia/idiopathic pulmonary 
fibrosis (UIP/IPF) pattern  and  stable  disease  by  symptoms,  PFTs,  and 
HRCT are monitored without specific therapy (other than treatment of their 
articular disease), as no therapy has been shown to improve this type of 
lung disease. Typically, these latter patients are older, and their RA-ILD is 
unlikely  to  respond  to  glucocorticoids  or  immunosuppressive  therapies. 
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Therapy of their joint disease continues as indicated, although any drugs 
that are associated with lung toxicity are discontinued. 
 
Indications for treatment — 
 
 
Features that suggest that treatment of RA-ILD is likely to be 
beneficial include younger age, histopathologic patterns other than UIP, and 
worsening of symptoms, PFTs, or HRCT over the preceding three to six 
months.  The  decision  to  commence  therapy  is  also  influenced  by  the 
presence of comorbid disease that might increase the risk of adverse effects 
(eg, diabetes mellitus, osteoporosis). 
 
 
 
 
 
Some clinicians would also treat selected patients with a radiographic 
UIP pattern of RA-ILD who are young, have a shorter duration of ILD, and 
deteriorating lung function, but no significant comorbid problems. This 
approach was addressed in a retrospective study of 144 patients with RA- 
UIP  of  whom 41  percent  received  immunosuppressive  treatment  due  to 
poor initial lung function or ILD progression. 
 
 
 
 
 
After a median follow up of 33 months, 50 percent of those treated 
had improved or remained stable, despite an expectation that these patients 
would be most likely to progress. Furthermore, there was no difference in 
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outcome  between the  treated and untreated groups, despite  worse initial 
lung function in the treatment group. This study, while not randomized, 
would suggest that the outlook with treatment is better in RA-UIP than IPF 
or that the clinical diagnosis of RA-UIP is not accurate and may include 
patients with RA-NSIP, shown to have a better prognosis and response to 
treatment. Thus, treatment with a goal of slowing disease progression may 
reasonably be considered in such patients, while awaiting further data. 
 
Patients with the organizing pneumonia, nonspecific interstitial pneumonia, 
and lymphocytic interstitial pneumonia histopathologic types of RA-ILD 
are   believed   to   be   likely   to   respond   to glucocorticoid/   immune- 
suppressive therapy based on experience with the idiopathic forms of these 
ILDs and on clinical reports. 
 
 
 
 
 
Initiation of glucocorticoid therapy — 
 
 
Glucocorticoid  therapy  produces  variable  subjective  and 
objective improvement in the treatment of RA-ILD, although some of the 
reported variability in response may be due to a lack of precision in 
determining the histopathologic subtype . As with the idiopathic interstitial 
pneumonias, the results may depend upon the relative proportions of 
inflammatory or fibrotic changes within the pulmonary parenchyma . 
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For symptomatic patients with RA-ILD, evidence of progressive 
respiratory  impairment,  an  amenable  histopathologic  type  (ie,  non-UIP 
based on HRCT or biopsy), and no evidence of lung infection, we suggest 
initiating therapy with oral prednisone at a dose of 0.5 mg/kg per day, based 
on ideal body weight as a single  morning dose . A maximum dose of 
60 mg/day should  not  be  exceeded,  as  there  is  no  clear  benefit  but 
significant risk above this level. If a response is going to occur, it is usually 
seen within one to three months. The prednisone dose should be slowly 
reduced to a maintenance dose of 10 mg/day once a response occurs, using 
symptomatic response and pulmonary function tests to monitor disease 
activity. 
 
In severe, rapidly progressive disease, after excluding infection, 
glucocorticoids are administered intravenously, as described for fulminant 
disease. 
 
 
 
 
 
Failure to respond to systemic glucocorticoids — 
 
 
Patients  who  fail  to  respond  to  glucocorticoids  alone  may 
benefit     from     addition     of     an     immunosuppressive     agent,     such 
as mycophenolate, azathioprine, or cyclophosphamide, although evidence in 
favor of this practice is limited to case series and clinical experience. After 
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excluding infection or drug-toxicity as a cause for the failure to respond, 
one of these agents is added to the ongoing prednisonedose; as examples, 
azathioprine (eg, 3 mg/kg orally up to 200 mg/day), mycophenolate mofetil 
(eg,  250  mg  given  twice  a  day  initially  with  a  target  dose  of  1.5  to 
2 g/day), or cyclophosphamide (eg, 100 to 120 mg orally/day as a single 
daily dose). Given the toxicity of cyclophosphamide, use of this drug is 
generally reserved for more severe or refractory disease. The dosing and 
potential adverse effects of these agents are discussed separately. 
 
 
 
 
 
Evidence  in  favor  of  mycophenolate comes  from  a  series  of  125 
patients with connective tissue-related ILD, including 18 with rheumatoid 
arthritis . Mycophenolate mofetil was associated with modest improvements 
in   forced   vital     capacity   and   diffusing   capacity   and   reductions   in 
theprednisone dose (mean decrease among RA patients 20 mg). The 
discontinuation rate for adverse effects (gastrointestinal intolerance, hepatic 
transaminase elevation, cytopenia, and nonspecific symptoms) was under 10 
percent. 
 
Hydroxychloroquine was      used      successfully      in      combination 
with mycophenolate in a small case series, but is almost never used as a 
single agent. It is not known whether pirfenidone and N-acetyl cysteine, 
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which may be of benefit in idiopathic pulmonary fibrosis, have a role in the 
management of RA-ILD with a UIP pattern. 
 
We avoid methotrexate in patients with RA-ILD due to the risk of lung 
toxicity  from  methotrexate.  In  a  series  of  64  patients  with  RA  and 
preclinical ILD, progressive ILD was more frequent in those treated with 
methotrexate                      than                      other                      medications 
(eg, prednoisone, leflunomide, hydroxychloroquine,  tumor  necrosis  factor 
[TNF]-alpha inhibitors or nonsteroidal anti-inflammatory drugs), suggesting 
that methotrexate is not optimal in this setting . 
 
 
 
 
 
Inability to taper glucocorticoids or intolerance of adverse effects — 
 
 
For patients who are unable to taper the glucocorticoid dose or have 
intolerable adverse effects, addition of an immunosuppressive agent may 
enable successful tapering of the glucocorticoids. Although published 
experience in RA-ILD is limited, this approach is used for several of the 
idiopathic            interstitial            lung            diseases].            As            an 
example, mycophenolate or azathioprine can   be   added   at    the  doses 
described above, while continuing prednisone at as low a dose as possible 
(eg, 0.2 to 0.25 mg/kg per day, or ≤10 to 15 mg daily). 
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Fulminant disease — 
 
 
For the minority of patients who develop rapidly progressive acute 
interstitial lung disease or organizing pneumonia as a complication of RA, 
after   excluding   infection   and   drug-induced  lung  toxicity,  we  follow 
treatment regimens for the particular type of ILD (eg, acute interstitial 
pneumonitis, organizing pneumonia). As these patients typically have 
impending or actual respiratory failure, treatment typically includes high- 
dose  systemic  glucocorticoids  (eg,methylprednisolone 1  to  2  g  per  day 
given intravenously as a pulse or in divided doses for three to five days). An 
immunosuppressive   agent   may   be   added   at   the   same   time,   such 
as cyclophosphamide or azathioprine,  although  evidence  in  favor  of  this 
practice is lacking. 
 
Monitoring — 
 
 
For patients who are being treated with systemic glucocorticoids or 
other immunosuppressive therapy, monitoring for an objective response to 
treatment  is  generally  performed  at  one  to  three  month  intervals  with 
clinical assessment, serial chest radiographs or high resolution computed 
tomography, and PFTs (eg, spirometry, lung volumes, diffusing capacity 
[DLCO], six minute walk test with monitoring of oxygen saturation). 
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Monitoring  for  adverse  effects  of  therapy  for  RA-ILD  is  essential.  As 
examples: 
 
 
 
 
 
●Monitoring for hematologic and hepatic toxicity – 
 
 
 
 
 
Close hematologic monitoring is needed with all of the 
immunosuppressive agents (eg, monthly initially and then every three 
months).  Toxicity  of azathioprine is  partly  related  to  deficiency  in  the 
enzyme thiopurine methyltransferase (TPMT), and analysis of the TPMT 
gene prior to  the  administration  of  azathioprine  may  help  predict  those 
individuals   at   risk   for   severe   toxicity.   In   addition   to   hematologic 
monitoring, liver function tests are obtained monthly at first and then every 
three months. The pharmacology and adverse effects of azathioprine are 
discussed separately. With cyclophosphamide, liver function monitoring 
follows a similar frequency, while renal function is assessed every two to 
four weeks. Additional details about the administration and monitoring of 
these agents are provided in the table and separately . 
 
 
 
 
●Drug-induced pulmonary toxicity – 
 
 
Almost  all of  the disease  modifying antirheumatic drugs 
 
 
(DMARDs) and biologic therapies have been associated with lung toxicity, 
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so clinicians should keep this possibility in mind should unexpected 
worsening of ILD occur during therapy. 
An  important  clinical  question  is  whether  drugs  known  to  cause  lung 
toxicity should be avoided in patients with underlying lung abnormalities 
due  to  concern  about  potential  exacerbation.  A  systematic  review  has 
shown the overall risk of a drug reaction is low (1 percent), although if a 
reaction occurs, it often has a high mortality . Potentially life-benefiting 
antirheumatic medications should not necessarily be withheld for what 
appears  to  be  an  uncommon  side  effect,  but  such  patients  do  require 
ongoing monitoring for worsening respiratory symptoms or function. 
●Infection – 
 
 
A variety of serious infections have been described with use of 
these immunosuppressive therapies. Prophylaxis against PCP may be 
warranted for some of the above treatment regimens. While the low doses 
of prednisone and methotrexate typically   used   in   RA   do   not   warrant 
prophylaxis, the combination of a glucocorticoid dose equivalent to ≥20 mg 
of  prednisone  daily  for  one  month  or  longer  and  a  second 
immunosuppressive  agent  or  the  combination  of  an  anti-tumor  necrosis 
factor-alpha agent with other intensive immunosuppression may warrant 
prophylaxis. 
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Vaccination with the influenza vaccine should be provided annually to 
all patents with rheumatoid arthritis. Administration of the polysaccharide 
pneumococcal vaccine is recommended in all adults with chronic lung 
disease. In addition, a second dose of the polysaccharide vaccine five years 
after   the   first   is   suggested   in   patients   receiving   immunosuppressive 
therapies. The pneumococcal conjugate vaccine is also suggested in such 
patients. 
 
 
 
 
●Prevention of osteoporosis – 
 
 
For  patients  on  long-term  oral  glucocorticoids,  osteoporosis  is  a 
concern, and oral calcium and vitamin D supplementation are recommended 
(eg, daily calcium 1200 mg and vitamin D 800 international units) for 
prophylaxis. Depending on the patient’s age and baseline bone density, 
pharmacologic therapy (eg, bisphosphonates) may also be indicated. The 
prevention and treatment of osteoporosis are discussed separately. 
●Cyclophosphamide and hemorrhagic cystitis – 
 
 
A  high  fluid  intake  is  encouraged  to  prevent  hemorrhagic 
cystitis with cyclophosphamide. 
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●Malignancy – 
 
 
Patients on long-term therapy with cytotoxic medications are at 
risk of developing malignancy, particularly skin, cervical, and, 
withcyclophosphamide, bladder cancer. Thus, patients should be educated 
about avoidance of the sun and use of sunblock, and women should receive 
regular mammograms and cervical Papanicolaou smears. 
Lung transplantation and novel therapies — 
 
 
Lung transplantation may be an option in end-stage RA-ILD. 
Among ten patients with RA-ILD who underwent lung transplantation, 
survival at one year was comparable to lung transplantation recipients with 
idiopathic pulmonary fibrosis, 67 and 69 percent, respectively . A modest 
improvement in quality of life with respect to respiratory symptoms was 
also noted. Side effects of the therapy for RA (eg, osteoporosis) may be a 
contraindication; other extrapulmonary disease manifestations may also 
complicate transplantation. 
 
The potential  role of  newer therapies  for RA (eg, rituximab, 
anti-TNF alpha regimens, abatacept, tocilizumab) in ameliorating RA-ILD 
is awaited with interest . In a case series, rituximab was administered in an 
open-label fashion to 10 patients with progressive RA-ILD of the UIP or 
NSIP types . Lung disease appeared to stabilize in four and improve in one, 
although  three  patients  withdrew  due  to  adverse  effects  (eg,  infusion 
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reactions, heart failure, possible pneumonia). Any potential benefit of anti- 
TNF-alpha therapy should be viewed in the context of several cases of 
rapid, occasionally fatal progression of lung disease in patients with RA- 
associated ILD treated with anti-TNF therapy . Abatacept and tocilizumab 
have had a beneficial effect in case reports, although tocilizumab has also 
been reported to have adverse lung effects as discussed above. 
 
 
 
 
 
PROGNOSIS — 
 
 
The prognosis of RA-ILD depends on the histopathologic subtype . 
For  many  patients  with  RA-ILD,  the  pulmonary  abnormalities  do  not 
progress and may remain subclinical. The effect  of presumed 
histopathologic  subtype  was  assessed  in  a  retrospective  review  of  144 
patients with RA-ILD, using high resolution computed tomography and, in 
a smaller number of patients, pathology . The poorest prognosis at five 
years was in those with diffuse alveolar damage (DAD) (20 percent) and 
usual  interstitial  pneumonia  (37  percent),  while  a  better  prognosis  was 
found for organizing pneumonia (60 percent), bronchiectasis (87 percent), 
bronchiolitis (89 percent), and nonspecific  interstitial pneumonia (94 
percent). In a separate retrospective review of 84 patients with RA-UIP who 
were monitored for 33 months, respiratory abnormalities remained stable in 
approximately  50  percent,  progressed  in  30  percent,  and  deteriorated 
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rapidly in 17 percent. Importantly, the stable group remained stable for a 
median of 45 months . 
 
 
 
 
 
Data  from  the  United  States  National  Center  for  Health  Statistics 
suggest that overall mortality rate from rheumatoid arthritis decreased 
between the years 1988 and 2004 (from 52.4 to 45.3 per 10 6 in women and 
23.3 to 15.3 per 106 in men) . However, during that interval mortality rates 
 
due to RA-ILD increased 28 percent in women (from 2.4 to 3.1 per 10 6) and 
declined 12 percent in men (from 1.7 to 1.5 per 10 6). Overall, RA-ILD was 
associated with a slightly shorter survival (approximately three years) 
compared with RA without ILD. 
 
The histopathologic similarity of RA-ILD and IPF has led to studies 
comparing their respective outcomes, but these studies have yielded 
conflicting results. In one case-control study comparing 18 patients with 
RA-ILD versus 18 patients with IPF, the median survival was greater for 
patients with RA-ILD (60 versus 27 months) . In a separate series of 86 
patients with RA-ILD and 872 with IPF, survival was similar between the 
two groups . 
 
A diffusion capacity less than 55 percent is an indicator of a poor 
prognosis . 
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In  one  study,  80  percent  of  patients  whose  disease  progressed  had  a 
diffusion capacity less than 54 percent (ie, 80 percent sensitivity) and 93 
percent of patients whose disease did not progress had a diffusion capacity 
greater than 54 percent (ie, 93 percent specificity). It seems likely that 
prognosis is also related to the histopathologic pattern, although data are 
lacking. 
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MATERIALS AND METHODS 
 
 
 
 
 
 
• STUDY POPULATION: 
 
 
This  study  is  to  be  conducted  in  known  RA  adult  patients  attending 
 
 
Medicine / Rheumatology OPD. 
 
 
 
 
 
 
• INCLUSION IN CRITERIA: 
 
 
Those patients satisfying 2010 ACR / EULAR criteria for classification of 
 
 
RA were included in the study. 
 
 
 
 
 
 
• STUDY DESIGN: 
 
 
50 adult rheumatoid arthritis patients (25 naïve and 25 on treatment) 
attending Medicine / Rheumatology OPD    in Madurai Medical College 
were included in the study. 
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STUDY PROTOCOL 
 
 
 
 
• DESIGN OF STUDY: 
 
Cross sectional study 
 
 
 
 
• PERIOD OF STUDY: 
 
4 months (JULY 2014 TO OCTOBER 2014) 
 
 
 
 
• COLLABORATING DEPARTMENTS: Department of 
 
 
 
Medicine, Department of 
 
 
 
Thoracic medicine Department of 
Rheumatology Department of 
Radiology, 
 
 
 
 
• ETHICAL CLEARANCE: Obtained 
 
 
 
• CONSENT: Individual written and informed consent. 
 
 
 
• ANALYSIS: STATISTICAL ANALYSIS 
 
 
 
• CONFLICT OF INTEREST: NIL 
 
 
 
• FINANCIAL SUPPORT: NIL 
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• PARTICIPANTS: 
 
 
 
50 adult patients attended Medicine / Rheumatology OPD of Govt. 
Rajaji Hospital, Madurai 
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RESULTS 
 
TABLE-1: SEX DISTRIBUTION  OF PATIENTS WITH 
RA 
 
 
 
 Male Female 
Treatment naive 4 21 
On treatment 12 13 
 
 
 
 
 
50  patients  with  rheumatoid  arthritis  who  presented  to  Madurai 
medical  college, Madurai over  a period of  4  months  were included the 
study. This included 34 females and 15 males [M: F ratio 1:2]. 
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TABLE-:2 
 
 
AGE DISTRIBUTION  OF PATIENTS IN TREATMENT NAIVE 
 
 
 
 
 
Age 
 
Frequency 
 
Percent 
20 – 29 yrs 3 12 
30 – 39 yrs 2 8 
40 – 49 yrs 7 28 
50 – 59 yrs 10 40 
60 – 69 yrs 2 8 
70 – 79 yrs 1 4 
Total 25 100 
 
 
 
 
 
 
 
 
 
AGE DISTRIBUTION  OF PATIENTS ON TREATMENT 
 
 
 
 
Age 
 
Frequency 
 
Percent 
20-29yrs 1 4 
30-39yrs 5 20 
40-49yrs 5 20 
50-59yrs 12 48 
60-69yrs 2 8 
70-79yrs 0 0 
Total 25 100 
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  N 
 
Mean 
 
SD 
 
Minimum 
 
Maximum 
Age 25 47.56 10.91 23 65 
 
 
 N MEAN S.D Minimum Maximum 
Age 25 47.64 11.3 25 70 
 
 
 
 
 
 
 
 
 
 
 
 
4 patients (7.5%) patients were aged between 20 -29 years 
 
7 patients were aged between 30-39 years 
 
12 patients were aged between 40 – 49 years 
 
22 patients were aged between 50 – 59 years 
 
4 patients were aged between 60-69 years 
 
1 patients was present in the age group between 70 – 79 years 
 
Mean age was 47 years 
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TABLE–3 
INCIDENCE  OF RESPIRATORY  SYMPTOMS IN PATIENTS 
WITH RA 
 
 
 
 
 
 
 
 
 
Respiratory 
Symptoms 
Frequency Percent 
new On Ɽ New On Ɽ 
No Symptoms 22 20 88% 80% 
Breathlessness - - - - 
Cough 3 2 12% 8% 
Wheezing - 2 - 8% 
NasalAllergy - 1 - 4% 
Breathlessness+Cough - - - - 
Total 25 25 100 100 
 
 
 
 
 
 
8 patients had respiratory symptoms. The symptoms included dry cough 5 
(10%) patients, wheezing 2 (4%), and nasal allergy 1 (2%). 
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TABLE–4 
 
FUNCTIONAL CLASS OF PATIENTS WITH RA 
 
 
 
 
 
 
CLASS–I 
 
 
CLASS–II 
 
 
New 
 
On 
Treatment 
 
 
New 
 
 
On treatment 
 
 
23 
 
 
18 
 
 
2 
 
 
7 
 
 
 
41 patients were in functional class I 
 
 
 
9 patients were in functional class II, none of the patients included in the 
study were in functional class 3 and 4. 
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TABLE– 5 
 
DURATION OF TREATMENT OF METHOTREXATE 
IN PATIENTS  WITH RA 
 
 
 
 
On methotrexate Frequency percent 
3-6 years 13 45% 
More than 6 years 12 55% 
total 25 100% 
 
 
 
 
 
 
Out of 25 patients 13 patients were on treatment for 3 -6 years and 12 
were on treatment for more than 6 years. 
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TABLE-6: 
PFT ABNORMALITIES IN PATIENTS WITH RA 
TYPE AND SEVERITY 
 
 
 
 
 
 
PFT Finding 
 
 
 
Frequency 
 
 
 
Percent 
   
 
 
 
New 
 
 
 
 
 
On treatment 
 
 
 
 
 
New 
 
 
 
 
 
On treatment 
 
 
Obstruction 
 
4 
 
5 
 
16% 
 
20% 
 
 
Restriction 
 
10 
 
11 
 
40% 
 
44% 
 
 
Normal 
 
11 
 
9 
 
44% 
 
36% 
 
 
 
Total 
 
 
 
25 
 
 
 
25 
 
 
 
100% 
 
 
 
100% 
 
 
 
In Newly diagnosed group 56 % had abnormal PFT this included 4(16%) 
 
 
obstructive, 10 (40 %) restrictive pattern 
 
 
Among the obstruction 2 (8%) were mild, 2(8%) moderate. 
Among the restriction 9(36%) were mild, 1(4%) moderate 
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On treatment group: 
 
 
 
 
 
16 patients (64%) had abnormal PFT this included 5 (20%) obstructive, 11 
(44%) restrictive 
Among obstructive – 4 (16%) were mild, 1 (4%) severe. 
 
 
Among restrictive – 8 (32%) were mild, 2 (8%) were moderate, 1 (4%) 
 
 
severe. 
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TABLE 7 
 
 
GENDER DISTRIBUTION  OF PFT FINDINGS 
 
 
 
PFT 
Finding 
Gender  
Total 
Male Female 
I II I II I II 
Obstruction 2 5 2 - 4 9 
 8% 20% 8 - 16% 20% 
Restriction 2 4 8 7 10 11 
 8% 16% 32% 28% 40% 44% 
Normal 0 2 11 7 11 9 
 0% 8% 44% 28% 44% 36% 
Total 4 11 21 14 25 25 
 16% 44% 84% 56% 100% 100% 
 
 
 
 
 
Chi-SquareValue
 
df 
 
‘p’value 
 
0.107 
 
1 
 
0.744 
 
 
 
 
 
 
 
Treatment naïve group: 2 (8%) patients out of 4 patients with obstruction 
were males and 2 (8%) were females .2 (8%) out of 10 patients with 
restrictive were males and 8 (24%) patients were females and 11 patients 
had normal PFT. 
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On treatment group: 
 
 
5 (20%) patients out 5 were male had obstructive pattern 
 
 
4 (16%) patients out of 11 with restrictive were male , 7 (28%) were 
female. 
2 (8%) out of 9 patients with normal PFT were male , 7 (28%)were 
female. 
More patients among females had restriction were compared to males this 
is statistically significant P value 0.0001. 
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TABLE-8 
AGE WISE DISTRIBUTION  OF PFT FINDINGS 
 
 
 
 
 
 
PFT 
 
Age in Years 
 
20-29 yrs 
 
30-39 yrs 
 
40-49 yrs 
 
50-59 yrs 
60-69 
 
yrs 
70-79 
 
yrs 
I II I II I II I II I II I II 
 
 
Obstruction 
- - - - 2 - 2 4 - 1 - - 
- - - - 8% - 8% 16% - 4% - - 
 
 
Restriction 
1 - 1 2 3 2 4 6 1 1 1 - 
4% - 4% 8% 12% 8% 16% 24% 4% 4% 4% - 
 
 
Normal 
2 1 1 3 2 3 4 2 1 - - - 
8% 4% 4% 12% 8% 12% 16% 8% 4% - - - 
 
 
Total 
3 1 2 5 7 5 10 12 2 2 1 - 
12% 4% 8% 20% 28% 20% 40% 48% 8% 8% 4% - 
 
 
 
 
 
 
 
 
Chi- d ‘p’val 
16.7 4 0.002 
76  
 
TREATMENT NAIVE: 
 
 
3  patients  were in  the  age group  of 20  –  29  years  , 1  (4%)  had 
restrictive pattern and 2 (8%) had normal PFT. 
2 patients were in the age group of 30 -39 years 1 (4%) had restrictive 
pattern and 1(4%) had normal PFT 
7  patients  were  in  the  age  group  of  40-49  years  .  2  (8%)  had 
obstructive  pattern  and  3  (12%)  had  obstructive  and  2  (8%)  had 
normal PFT. 
10 patients were in the age group of 50 to 59 years , 2 (8%) had 
obstructive pattern and 4 (16%) had restrictive and 4(16%) had normal 
PFT. 
2  patients  were in  the  age group  of 60  –  69  years  , 1  (4%)  had 
obstructive pattern and 1 (4%) had restrictive 
1 patients were in the age group of 70 – 79 years and had restrictive 
pattern 
The incidence of PFT abnormality in the age group of 50 to 59 years 
was high  when compared to other age group this  was statistically 
significant. 
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On treatment group: 
 
 
One patients was in the age group of 20-29 Years , Who had Normal 
 
 
PFT. 
 
 
5 Patients were in the age group of 30-39 Years ,2 had restrictive 
and 3 had normal PFT. 
5 Patients were in the age group of 40-49 Years ,2 had restrictive 
and 3 had normal PFT. 
12 Patients were in the age group of 50-59 Years ,4  had obstructive, 
 
 
6 had  restrictive and 2 had normal PFT. 
 
 
3 Patients were in the age group of 60-69 Years ,1 had obstructive, 
 
 
1 had  restrictive and 1 had normal PFT. 
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TABLE-9 
 
 
SEVERITY OF PFT ABNORMALITY CORRELATED  WITH 
SYMPTOM DURATION ON TREATMENT GROUP 
 
 
  
Total 
3- 6 years >6 yrs  
 
Mild 
4 2 6 
16% 8% 24% 
 
Moderate 
2 1 3 
8% 4% 12% 
 
Severe 
1 1 2 
4% 4% 8% 
 
 
 
Normal 
2 1 3 
8% 4% 12% 
 
Total 
13 12 25 
52% 48% 100% 
 
Chi-SquareValue df ‘p’value 
0.422 2 0.81 NS 
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13 patients were on treatment for 3 – 6 years of them 7 patients had 
abnormal PFT4 (16%) patients had mild PFT abnormality , 2 (8%) had 
moderate PFT abnormality , 1 (4%) had severe PFT abnormality and 2 
patients had normal PFT. 
12  patients  were on  treatment  for more  than  6  years  , of them 6 
patients had abnormal PFT ,  3 (12%) had mild PFT abnormality , 2 (8%) 
had moderate PFT abnormality , 1 (4%) severe PFT abnormality , 1 had 
normal PFT. 
No statistical correlayion was found between the severity of PFT 
 
 
abnormality and duration of disease was found. 
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Chi- Square Value df ‘p’ value 
0.814 1 0.004 
 
 
 
TABLE-10 
 
 
 
 
 
ABNORMAL PFT CORRELATED WITH 
FUNCTIONAL  CLASS IN ON TREATMENT GROUP 
 
 
 
PFTFinding 
FunctionalClass  
Total 
Grade1 Grade2 
 
Obstruction 
2 3 5 
8% 12% 20% 
 
Restriction 
5 6 11 
20% 24% 44% 
 
Normal 
9 0 9 
36% 0% 36% 
 
Total 
16 9 25 
64% 36% 100% 
 
 
 
 
 
 
 
 
 
 
 
 
\ 
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5 patients had obstructive PFT , among them 2 (8%) were in functional 
class I and 3 (12%) patients were in functional class II . 11 patients had 
restrictive PFT   , 5 (20%) were in functional class I , 6 (24%) were in 
functional class II , 9 patients had normal PFT. 
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DISCUSSION 
 
 
 
 
 
 
 
Rheumatoid   arthritis (RA) is a chronic multi-system   disease of 
unknown cause. It is a systemic inflammatory  disease and affects 1-2% of 
the general population. A major portion of morbidity and mortality are due 
to RA are due to its extra-articular manifestations A variety of pulmonary 
manifestations are associated with RA6    and lung disease is the second 
most common cause of death (18%) after infection (27%) inpatients with 
 
RA. Pleuro-pulmonary manifestations occur more commonly in men. 
Pulmonary function test abnormalities in RA can be restrictive (19-44%) if 
there is pleural or parenchymal involvement, or obstructive (16-38%) if 
there is obliterative bronchiolitis, bronchiectasis or cricoaryetenoid 
arthritis23. 
 
 
In our study the female to male ratio was 2:1. In a study conducted 
by Arnett FC et al, RA has a 3:1 predilection for women between the ages 
of twenty and fifty years107.In a study conducted by RanigaS, Sharma 
Petal in 2006, the female to male ratiowas 3:1108.The male to female ratio 
ranges from 1:2 to 1:4. 
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The average age of patients in our study was 46.5years.The mean 
age of onset of pulmonary disease was in the fifth or sixth   decade. In a 
study conducted by Raniga etal, average age of male patients was  48.4 
years and for females 45.8years108.The mean duration of illness was 34.8 
months. The mean age of onset of lung disease was in the fifth or sixth 
 
decade. The average age of patients in our study was comparable to that of 
other studies. However the mean duration of illness in our study was more 
than the other studies. 
 
 
 
 
Rheumatoid factor results: 
 
 
RA factor was positive in 70% of patients with RA in our study. RA 
factor was positive in twenty-five patients (83.3%). In the study by Raniga 
et al nearly 3/4th of patients with RA have rheumatoid factor positivity 109. 
 
 
Respiratory symptoms and signs: 
 
 
 
 
 
In our study patients with respiratory symptoms were 16%. Patients 
presented with cough, breathlessness, wheeze and   combination of these. 
7%   had   clinical   evidence   of   respiratory  involvement.   In   the   study 
conducted  by  Raniga  et  al,  six  of  the  thirty  patients  had  respiratory 
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complaints (20%)108. The symptoms included cough, breathlessness, 
wheeze, sputum production and chest pain. Only three patients(10%) had 
 
clinical evidence of respiratory involvement [presence of rhonchi and 
crackles]. In our study, more patients had respiratory signs than those who 
had respiratory symptoms. 
 
 
 
PFT abnormalities  in patients with rheumatoid  arthritis: 
 
 
Fifty patients underwent pulmonary function testing. 56% patients 
had abnormal PFTs 16% had obstructive and 40% had restrictive pattern in 
treatment naive and 64% patient had abnormal PFTs 20% had obstructive 
and 44% had restrictive pattern in on treatment group. Majority of patients 
in  both  restrictive  and  obstructive  group  had  mild  abnormality,  lesser 
number of patients had moderate abnormality and very few patients had 
severe  PFT abnormality.  The  incidence of obstructive  PFT abnormality 
was more common in male patients in our study. 
In    patients with RA, bronchiectasis is more common in women 
(male  to female ratio of 1:2.8). However, other causes of obstruction like 
obstructive bronchiolitis and follicular bronchiolitis are more common in 
men. 
In our study patients with radiologically overt bronchiectasis were 
less. Hence there was a male preponderance with respect to obstructive 
defect. 
85  
The incidence of restrictive PFT abnormality was more common in 
female patients in our study. However, the incidence of ILD and pleural 
involvement  that  causes  restriction  is  more  common  in  men  a  study 
conducted by Gabbay et al79. In our study more female patients had 
restrictive PFT abnormality. This could be explained by the fact that only a 
 
small number of patients with RA were screened for lung involvement. 
Hence, they may not    actually reflect the    patients with ILD having 
restrictive PFT abnormality. 
Majority of patients with PFT abnormality in our study were in the 
fifth and sixth decades. The difference between the age groups were not 
statistically significant. 
In the study conducted by Raniga et al, spirometric evidence of lung 
 
involvement was present in eight patients (26.6%) 108. Maximum abnormal 
PFTs were noted in the fifth and sixth decade. However the difference 
between  the  abnormalities  in  the  age  groups  were  not  statistically 
 
 
significant. 
 
 
In the study conducted by Fuld et al, the maximum abnormal PFTs 
were in the age group of 40-69 years with the peak incidence in the age 
group of 50-59. PFTs abnormalities were more in patients with respiratory 
symptoms when compared to those without them. 
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In the study conducted by Vitali.C et al, PFT abnormalities were 
 
 
seen more in patients with respiratory symptoms 110. 
 
 
In our study, spirometric evidence of lung involvement was  seen in 60%. 
 
 
21(48.5%) patients out of 44 asymptomatic patients had an abnormal PFT. 
 
 
In  the  study  conducted  in  2006  by  Raniga  N  et  al,  spirometric 
 
 
evidence  of  lung  involvement  was  present  in  eight  patients 108.  Thus, 
spirometric abnormalities could be detected in asymptomatic patients also. 
HRCT was abnormal in eleven patients (36%) and hence more sensitive 
than spirometry to detect pleuropulmonary involvement in patients of RA. 
Spirometry picked up a larger number of abnormal PFTs in our study. 
Abnormalities were also seen in a significant number of a symptomatic 
patients. 
Restrictive  PFT abnormality 
 
 
In our study, patients with reduced FVC was observed in 19 (37%) 
patients. Thirty nine patients (52%) had abnormal PFTs. 6 (15.4%) patients 
among the patients with abnormal PFTs had an abnormal chest radiograph. 
3 (10.7%) patients with restrictive PFT abnormality had radiological 
evidence of reticular opacities. 3 (27.3%)    patients with obstructive PFT 
had  radiological  evidence  of  hyperinflation.  2(6%)  patients  who  had 
normal PFTs had an abnormal X-ray. Hence PFTs were more sensitive in 
detecting pulmonary abnormalities than chest radiographs. However when 
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both these investigations were used together, the yield of pulmonary 
abnormalities was better than either test alone. 
In a study conducted by McDonagh et al, spirometric abnormalities were 
 
 
noted in 8/30 (26.6%) and radiological abnormality in 13% 62. In a study 
conducted  by  Laitinen  O  et  al,  vital  capacity  (VC)  and  single-breath 
 
diffusing capacity for carbon monoxide of the lungs (DLco) were measured 
and  chest  X-ray  evaluated  in  129  patients  with  rheumatoid  arthritis 
(RA)83.Findings in the 123 cases were observed as follows: in one of the 
lung function tests or X-ray examinations, 35%; abnormal X-rays, 18%; 
 
reduced VC 28%; simultaneously low VC and Dco, 7%; and pathological 
findings in all three tests,2%. The patients with abnormal X-rays showed 
extremely  low  VC  and  Dco  values.  Changes  in  respiratory  function 
involved  restrictive  impairment  and  diffusion  defects,  and  the  results 
further implied that restrictive changes develop early, where as decreased 
diffusing capacity is associated with more advanced  rheumatoid lung. The 
disparity abnormal findings in chest X-ray changes and in lung function 
tests suggests that in examining pulmonary manifestations in patients with 
RA, both radiographic methods and pulmonary function tests should be 
used for relevant evaluation 
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The incidence of restrictive lung disease in our study was 37%. Most 
patients had mild restriction, lesser patients had moderate and least had 
severe restriction. Interstitial lung disease occurs in 19% of patients with 
RA irrespective of respiratory symptoms, however, early interstitial lung 
changes and subclinical alveolitis have been found in upto 40% of RA 
patients in a study conducted b y Eisenberg H, McDonagh J et al62. Mean 
age at onset of ILD was the fifth or sixth decade. The HRCT study by 
 
Fewins et al of patients with RA  revealed a high prevalence of ILD(44%) 
 
 
with maximum patients having mild restriction and lesser patients having 
 
 
moderate and severe restriction112. In the study conducted by Raniga et al, 
when all forms of HRCT diagnosed abnormalities are combined, there was 
 
a closer prevalence (37%) of ILD to the other studies. In a study conducted 
by McDonagh  et  al, HRCT  findings  consistent  with  ILD  were  seen in 
eleven out of thirty patients(36%), compare to the spirometric findings in 
8/30(26.6%). The results of HRCT have not been shown to correlate with 
pulmonary function tests. 
 
 
 
 
 
 
 
Obstructive  PFT abnormality: 
 
 
In our study, 9(18%) patients had evidence of obstruction on PFTs 
which was comparable to the reported prevalence of airway disease in RA. 
In a study conducted by Doyle et al in 2004, the pulmonary abnormalities 
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included two patients with hypoxia(12%), two with obstruction (12%), and  
 
 
three with restriction (18%) and four with AHR (23%)105. In a PFT survey 
of patients with rheumatoid arthritis, airway obstruction was observed in 9- 
 
37%, even in non-smoking patients. Perez T et al studied 50 patients with 
RA (ninemalesand41 females;meanage:57.8yr), which included 39 
nonsmokers  and  11  smokers(meancigaretteconsumption:15.3pack-yr) 
without radiographic evidence of RA-related lung changes. PFTs 
demonstrated airway obstruction (i.e., reduced  FEV1/VC) in nine patients 
(18%) compared to HRCT which picked up an abnormality in 70% of 
patients. In the study conducted by Fuld et al, after exclusion of smokers, 
the proportion of airway obstruction in patients with rheumatoid arthritis 
was  16%(versus0%incontrols),  although  the  patients  with  rheumatoid 
arthritis still had more symptoms and respiratory disorders. 
 
 
 
 
 
 
 
Correlation  of PFT findings and duration  of disease: 
 
 
 
 
 
In  our  study the  number  of  patients  with  restriction  in  treatment 
naive group is 40% and in on treatment group is 44%. However there was 
no correlation between severity of PFT abnormality and the duration of 
disease. 
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In a study conducted by Cervantes-Perez et al, no correlation was 
found between the disease duration, the number of patients and the severity 
of restrictive PFT abnormality. This could be explained by the fact that 
most of our patients had subclinical ILD when compared to the series of 
Cervantes-Perez et al111. 
 
 
In our study the number of obstructive PFTs also increased as the 
disease duration   increased. However   there was no correlation observed 
between the disease duration and severity of PFT abnormality 
In a study conducted by Fuld et al, there was no relationship between 
the severity of obstructive abnormality, the duration of disease and type of 
treatment106. The data also suggest a strong association between 
pulmonary diseases in RA and cigarette smoking. 
 
In the study conducted by Fuld et al, there was no relationship 
between airway obstruction, duration of rheumatoid arthritis and type of 
treatment. There was also no correlation between the severity of PFT 
abnormality and the duration of the disease. 
In  the  study  by  Cervantes-Perez  et  al,  there  was  no  correlation 
between the number of patients with obstructive PFT abnormality and the 
duration of disease111 
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Correlation  of severity of PFT abnormality and duration  of 
disease: 
In a study conducted by Cervantes-Perez et al, no correlation was 
found between the disease duration, the number of patients and the severity 
of restrictive PFT abnormality. This could be explained by the fact that most 
of  our  patients  had  subclinical  ILD  when  compared  to  the  series  of 
Cervantes-Perez et al. 
In our study ,9 (18%) patients had evidence of obstruction on PFTs 
which was comparable to the reported prevalence of airway disease in RA. 
In our study the number of obstructive PFTs increased as the disease 
duration increased, but it was not statistically  significant. However  there 
was no correlation observed between the disease duration and severity of 
PFT abnormality 
 
In a study conducted by Fuld et al,there was no relationship between the 
severity of obstructive abnormality, the duration of disease and type of 
treatment. In a study conducted by Doyle et al in 2004, the pulmonary 
abnormalities included two patients with hypoxia (12%), two with 
obstruction (12%), and three with restriction (18%) andfour with AHR 
(23%). The data also suggest a strong association between pulmonary 
diseases in RA and cigarette smoking. In a PFT survey of patients with 
rheumatoid arthritis,airway obstruction was observed in 9-37%,  even in 
non-smoking patients. 
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PerezT et al studied 50 patients with RA nine males and 41 females 
 
 
; mean age: 57.8yr),  which included 39 nonsmokers and 11smokers (mean 
cigarette consumption: 15.3pack-yr) without radiographic evidence of RA- 
related lung changes. PFTs demonstrated airway  obstruction (i.e., reduced 
FEV1/VC) in nine patients (18%)  compared  to HRCT which picked up an 
abnormality in 70%of patients..In the study conducted by Fuld et al, the 
maximum abnormal   PFTs were in the age group of 40-69 years with the 
peak incidence     in the age group of 50-59 years.     After exclusion of 
smokers, the proportion of airway obstruction in patients with rheumatoid 
arthritis was 16% (versus 0% in controls), although the patients with 
rheumatoid  arthritis  still  had  more  symptoms  and  respiratory  disorders. 
There was no relationship between airway obstruction, duration of 
rheumatoid arthritis and type of treatment. There was also no correlation 
between the severity of PFT abnormality and the duration of the disease. 
 
 
 
 
 
 
 
Correlation  of PFT abnormality and functional class:. 
 
 
 
 
 
The abnormal PFTs were found more commonly in functional class- 
 
 
2. This implied that patients who  had a lung function abnormality on PFT 
had a more impaired functional class of RA. When the     severity of PFT 
abnormality was 
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correlated with functional class of rheumatoid arthritis it was found that 
more patients with moderate obstruction were in functional class2 when 
compared to patients with mild obstruction. The severity of obstruction 
increased  when  the  functional  class  of  patients  changed  to  class2  from 
class1. This implied that patients with more severe obstructive abnormality 
were functionally more limited when compared to those with a milder 
obstructive abnormality. 
 
 
 
Correlation  of DMARD and PFT abnormality: 
 
 
No patient in our study had methotrexate induced acute pneumonitis. 
Life-threatening acute methotrexate pneumonitis occurs in 0.3-11.6% of 
rheumatoid arthritis patients treated with methotrexate, usually with in the 
first   6 months. A recent report by Khadadah et al 98 showing significant 
deterioration in lung function after 2years of treatment with methotrexate 
 
raised the issue of chronic toxicity, but Dawson et al found no such 
deterioration inlung function over 2 years with methotrexate. There was no 
correlation   observed   between   the   duration   of   DMARDs   and   PFT 
abnormality in our study. However a longitudinal study is warranted to 
assess the impact of long term methotrexate and chronic lung toxicity 
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Radiological abnormalities: 
 
 
 
 
 
The incidence of radiological abnormality was 10.7%. with 37.5% of 
these patients showing reticulonodular opacities-The incidence of 
radiological abnormality ranges from 2-10% in patients with RA. Chest x- 
ray showed changes consistent with ILD in 9/150 (6%) patients with RA 
and X-ray  chest was normal in 18/28 (64.2%) patients with HRCT positive 
ILD. In the study conducted by Raniga et al,abnormalities detectable on 
chest radiograph were 13.33%,    chest x-ray showed changes consistent 
with ILD in 4/30 (13.3%) including bilateral reticular infiltrates in three 
and honeycombing in one and x-ray chest was normal in 7/11 (63.6%) 
patients with HRCT positive ILD. 
In a study conducted by FrankSI and PerezT et al, evidence of 
interstitial fibrosis is seen at chest radiography in approximately 5% of 
patients with rheumatoid arthritis and at HRCT in 30%-40%. The chest 
radiograph may be normal in patients with early fibros is Most of these 
patients had respiratory symptoms.In a study conducted by VitaliH et al, 
the prevalence of ground glass opacities (GGOs) on HRCT in patients with 
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out respiratory symptoms was only 3% and none had honeycombing, in 
contrast to 26 and 23%, respectively in patients with respiratory 
symptoms.[15] .Chest  radiograph  is  the  least  sensitive  in  detecting 
interstitial lung disease. In our study, the ability of PFTs to pick up an 
 
abnormality was better than the chest radiograph which were 52% and 
 
 
10.7% respectively. However when both these investigations were 
combined, the sensitivity was better than either test alone. 
In late stages, chest radiograph shows changes identical to that of 
Interstitial Pulmonary Fibrosis (IPF). Chest radiographs typically show a 
fine reticular or reticulonodular pattern involving the lower lung zones in 
early stages . With progression of disease, the reticular pattern becomes 
more coarse and diffuse, and honey combing may be seen. In our study the 
reticulonodular opacity consistent with ILD was seen in 3 (4%) of patients. 
This   accounted   for   37.5%   of   the   abnormal   chest   radiographs.The 
radiological abnormality was in the form of reticulonodular opacity 
consistent with the diagnosis of  ILD. 
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HRCT  shows evidence  of interstitial lung disease  in eleven out of 
thirty patients and so the most sensitive  of all parameters. It was evident 
that chest radiograph is the least sensitive in detecting interstitial lung 
disease.In our study, the ability of PFTs to pickup an abnormality was 
better than the chest radiograph which were 52% and 10.7% respectively. 
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CONCLUSIONS 
 
 
 
•  PFTs  are  a  sensitive  tool  in  picking  up  pulmonary  involvement  in 
rheumatoid arthritis. 
• The incidence of abnormal PFTs was maximum in the age group of 41-60 
years. 
• PFT abnormalities were found in a more than half of patients with RA in 
our study. 
• Restrictive lung disease was the commonest abnormality and was seenin 
 
 
1/3 rd of patients 
 
 
•  Obstructive airway disease was seen in 1/5 th of patients 
 
• Most  of  the  patients  had  mild  degree  of  restrictive  and  obstructive 
abnormalities 
• The   number   of   abnormal   PFTs   increased   as   the   disease   duration 
increased.There was no correlation between the disease duration and the 
severity of PFT abnormality. 
 
• PFT abnormalities were encountered with greater frequency in 
patients of higher functional class of disability in rheumatoid 
arthritis. 
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There is increased incidence of PFT abnormality in on treatment group 
when compared to treatment naïve group this may be explained by the type 
of lung involvement (ex. If the patient had usual interstitial pneumonia the 
lung disease may progress or remain static) . but a longitudinal study is 
warranted. 
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SUMMARY 
 
Lung involvement is one of the most important extra articular 
manifestations of rheumatoid arthritis. The incidence of restrictive lung 
disease observed in our study was 42%. A significant number of 
asymptomatic  patients  with  RA  had  abnormal  PFTs.  The  number  of 
patients with PFT abnormalities increased as the duration of rheumatoid 
disease increased but the severity of these abnormalities did not increase. 
These PFT abnormalities were more commonly observed in patients with 
more impaired functional class. Pulmonary function tests are a sensitive 
measure in detecting  early lung  involvement  in patients  with rheumatoid 
arthritis.  Pulmonary  function  testing  when  combined  with  chest 
radiography is cost effective and a good screening test for early detection 
of pleuro pulmonary involvement in patients with RA especially as HRCT 
and DLCO are not widely available and are expensive. 
 
 
 
 
A key component of the evaluation is determination of the type of ILD, as 
all of the histopathologic types of idiopathic interstitial lung disease can 
occur in the context of RA . Often the cause and type of ILD can be 
determined by the combination of clinical presentation, PFTs, and HRCT. 
In a minority of cases, when these features are not typical for a given type 
of ILD and the patient is symptomatic, fit for surgery, and the biopsy would 
change  the  therapeutic  approach  ,  characterization  of  the  ILD  by 
lung biopsy is often appropriate 
 
An  early  effort  to  diagnose  the  pattern  of  lung  involvement  is 
required for specific management. The prognosis of RA-ILD depends on 
the histopathologic subtype . For many patients with RA-ILD, the 
pulmonary abnormalities do not progress and may remain subclinical 
 
 
 
The improvement of pulmonary function depends upon the specific 
histopathology of lung involvement .Hence early diagnosis and appropriate 
therapy is needed for better quality of life in these patients. 
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ANNEXURE - I 
 
THE 2010 ACR-EULAR CLASSIFICATION CRITERIA FOR 
RHEUMATOID ARTHRITIS 
 
  
Score 
 
Target population (Who should be tested?): Patients who 
 
1. have at least 1 joint with definite clinical synovitis (swelling) * 
2. with the synovitis not better explained by another disease â€  
 
 
Classification criteria for RA (score-based algorithm: add score of 
categories A - D; 
a score of ≥6/10 is needed for classification of a patient as having 
definite RA)â€¡ 
 
 
A. Joint involvement  Â§ 
 
 
1 large jointÂ¶ 
 
0 
 
2-10 large joints 
 
1 
 
1-3 small joints (with or without involvement of large joints) # 
 
2 
 
4-10 small joints (with or without involvement of large joints)  
 
3 
 
>10 joints (at least 1 small joint) ** 
 
5 
 
B. Serology (at least 1 test result is needed for classification) â€ â€  
 
   
Score 
 
Negative RF and negative ACPA 
 
0 
 
Low-positive RF or low-positive ACPA 
 
2 
 
High-positive RF or high-positive ACPA 
 
3 
 
C. Acute-phase reactants (at least 1 test result is needed for 
classification) 
 
 
Normal CRP and normal ESR 
 
0 
 
Abnormal CRP or abnormal ESR 
 
1 
 
D. Duration of symptomsÂ§Â§ 
 
 
<6 weeks 
 
0 
 
≥6 weeks 
 
1 
 * The criteria are aimed at classification of newly presenting patients. 
In addition, patients with erosive disease typical of rheumatoid arthritis (RA) 
with a history compatible with prior fulfillment of the 2010 criteria should be 
classified as having RA. Patients with longstanding disease, including those 
whose disease is inactive (with or without treatment) who, based on 
retrospectively available data, have previously fulfilled the 2010 criteria 
should be classified as having RA. 
â€  Differential diagnoses vary among patients with different 
presentations, but may include conditions such as systemic lupus 
erythematosus, psoriatic arthritis, and gout. If it is unclear about the relevant 
differential diagnoses to consider, an expert rheumatologist should be 
consulted. 
â€¡ Although patients with a score of <6/10 are not classifiable as 
having RA, their status can be reassessed and the criteria might be fulfilled 
cumulatively over time. 
Â§   Joint   involvement   refers   to   any swollen or tender joint   on 
examination, which may be confirmed by imaging evidence of synovitis. 
Distal interphalangeal joints, first carpometacarpal joints, and first 
metatarsophalangeal joints are excluded from assessment . Categories of joint 
distribution are classified according to the location and number of involved 
joints, with placement into the highest category possible based on the pattern 
of joint involvement. 
Â¶ "Large joints" refers to shoulders, elbows, hips, knees, and ankles. 
 
 
# "Small joints" refers to the metacarpophalangeal joints, proximal 
interphalangeal  joints,  second  through  fifth  metatarsophalangeal  joints, 
thumb interphalangeal joints, and wrists. 
** In this category, at least 1 of the involved joints must be a small 
joint; the other joints can include any combination of large and additional 
small joints, as well as other joints not specifically listed elsewhere (e.g., 
temporomandibular, acromioclavicular, sternoclavicular, etc.). 
â€ â€  Negative refers to IU values that are less than or equal to the 
upper limit of normal (ULN) for the laboratory and assay; low-positive refers 
to IU values that are higher than the ULN but ≤3 times the ULN for the 
laboratory and assay; high-positive refers to IU values that are >3 times the 
ULN for the laboratory and assay. Where rheumatoid factor (RF) information 
is only available as positive or negative, a positive result should be scored as 
low-positive for RF. ACPA = anti-citrullinated protein antibody. 
â€¡â€¡ Normal/abnormal is determined by local laboratory standards. 
CRP = C-reactive protein; ESR = erythrocyte sedimentation rate. 
Â§Â§  Duration  of  symptoms  refers  to  patient  self-report  of  the 
duration of signs or symptoms of synovitis (e.g., pain, swelling, tenderness) 
of joints that are clinically involved at the time of assessment, regardless of 
treatment status. 
ANNEXURE - II 
 
PROFORMA 
 
 
 
 
 
 
DATE: 
 
 
 
HOSPITAL OP/IP NO: 
 
 
 
 
 
1.  NAME : 
 
 
 
 
 
 
 
2.  AGE : 
 
 
 
 
 
 
 
3.  SEX : 
 
 
 
 
 
 
 
4.  OCCUPATIONAL HISTORY : 
 
 
 
 
 
 
 
5.  HISTORY OF EXPOSURE TO POLLUTANTS: YES -/ NO- 
 
 
 
 
 
 
 
6.  PRESENTING COMPLAINTS – 
a.   RELATED TO MUSCULOSKELETAL SYSTEM – 
 
 
 
 
 
 
 
1.PAIN- 
 
 
 
 
 
 
 
2.SWELLING- 
 
 
 
 
 
 
 
3.RESTRICTION- 
 
 
 
 
 
 
 
4.DEFORMITY- 
 
 
 
 
 
 
 
b.  RELATED TO RESPIRATORY SYSTEM- 
 
 
 
 
 
 
 
i. COUGH - iv 
 
 
 
.EXPECTORATION- ii. BREATHLESNESS – 
 
 
 
v CHEST PAIN- 
 
 
 
 
iii. WHEEZE - vi HEMOPTYSIS- 
7.  HISTORY OF BRONCHIAL ASTHMA. YES -/NO- 
 
 
 
 
 
 
 
8.  HISTORY OF SMOKING : YES /NO- IF YES - 
TYPE OF TOBACCO- 
NUMBER OF 
BEEDIS/CIGARRETES- NUMBER 
OF YEARS SMOKED- SMOKING 
INDEX- 
 
(SMOKERS ARE EXCLUDED) 
 
 
 
 
 
9.  HISTORY OF COPD : YES-/NO- 
 
 
 
 
10. HISTORY OF PULMONARY TUBERCULOSIS- YES -/NO- 
 
 
 
 
11. TIME SINCE R A DIAGNOSIS- 
 
 
 
 
12. TIME SINCE ON MEDICATIONS- 
 
 
 
 
13. TREATMENT DETAILS- 
 
 
 
14. ON EXAMINATION – 
 
 
 
 
a. GPE- 
PALLOR:YES-/ NO- 
ICTERUS:  YES- 
/NO- CYANOSIS: 
YES-/NO- 
CLUBBING:YES- 
/NO- 
 
 
LYMPHADENOPATHY:YES- 
 
/NO- PEDAL EDEMA:YES-/NO- 
 
 
b.   SYSTEMIC EXAMINATION 
RESPIRATORY SYSTEM- 
CARDIOVASCULAR SYSTEM- 
CENTRAL NERVOUS SYSTEM 
- PER ABDOMEN- 
 
 
MUSCULOSKELETAL 
- SYSTEM 
 
MCP PIP WR EL SH MTP PIP AN KN HIP 
AA 
 
 
 
SWELLING- 
RESTRICTIO 
N- 
 
DEFORMITY- 
 
SPO 
 
 
 
2: INVESTIGATIONS: 
 
 
 
ROUTINE: 
 
 
 
 
 
 
CX 
 
 
 
R: PFT 
IMPRESSION: 
ANNEXURE- III 
 
 
 
 
 
FUNCTIONAL  CLASS OF RHEUMATOID 
ARTHRITIS 
 
 
 
 
 
GRADE-1  -NO  HANDICAP.  CAN  CARRY  ON  ALL  DAILY  ACTIVITIES 
GRADE-2  -MODERATE RESTRICTION OF ACTIVITIES BUT 
 
INDEPENDENT 
 
 
 
 
GRADE-3 -MARKED RESTRICTION OF ACTIVITIES MOSTLY LIMITED 
TO SELF CARE.NEEDS ASSISTANCE 
 
GRADE-4 -BED OR CHAIR BOUND. INCAPACITATED AND DEPENDENT 
LIST OF ABBREVIATIONS USED 
 
 
 
 
 
 
 
PFT -  Pulmonary function test 
RA - Rheumatoid Arthritis 
ILD - Interstitial lung disease 
BOOP - Bronchiolitis obliterans organizing pneumonia 
 
 
OB                        -           Obliterative bronchiolitis 
CB                        -           Constrictive bronchiolitis 
FB                         -           Follicular bronchiolitis 
NSIP - Non specific interstitial pneumonitis 
 
 
UIP - Usual interstitial pneumonitis 
 
 
DMARDs - Disease modifying antirheumatoid drugs 
 
 
MTX - Methotrexate 
 
 
HRCT – High Resolution computed Tomography. 
CXR –  Chest Radiogram 
FEV1 – Forced Expiratory Volume in First Second 
 
 
FVC – Forced Vital Capacity 
 
 
FEF 25-75/MMFR – Maximum Mid Expiratory Flow Rate 
 
 
PEFR – Peak Expiratory Flow Rate. 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
